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Breast cancer represents the most common cancer among women and, despite increased 
early detection and improved therapeutic approaches, it also remains among the deadliest 
cancer worldwide. Accumulating evidence has shed light on the correlation between 
oncogenic signalling and metabolic reprogramming in cancer cells, and ten years ago 
metabolic reprogramming has been included among the hallmarks of cancer. In breast cancer 
a de-regulated metabolism has been described both in patients previously untreated and in 
treatment-resistant populations. Relapses are believed to arise from residual cancer stem 
cells that survive the initial therapeutic treatment. Tumour relapse still represents the main 
cause of breast cancer related death. Therefore, a comprehensive understanding of cancer 
stem cell biology and metabolism is needed to eventually impair the formation of tumour 
relapses and obtain more effective therapies.  
In my Ph.D. research activity, I first investigated the correlation between lipid metabolism 
and breast cancer stem cells. Focusing specifically on lipid droplets (LD), the lipid storage 
organelle of the cell, I investigated the role of LD in breast cancer stem cells and 
tumorigenesis. Mammosphere assays and gene expression profiling, revealed a strong 
correlation between lipid droplet number and stemness in a panel of 4 different breast cancer 
cell lines. Furthermore, in vivo studies revealed the role of lipid droplets as a marker of cell 
harbouring increased tumorigenic capacity.  
The accumulation of lipid droplets in cancer cells is part of a more general metabolic 
reprogramming characterizing breast tumours. Indeed, from a metabolic perspective, breast 
cancer cells show high glycolytic rates, intense anabolic growth and an up-regulation of de-
novo fatty acid synthesis. Historically, a competitive relationship between glucose and fatty 
acid usage at the level of tissue metabolism was reported, with the cells ultimately relying 
upon only one of the two energy sources. In order to better dissect the role of lipid 
metabolism in breast cancer onset at a molecular level, I sought to investigate the previously 
described, but never elucidated, biochemical interplay between lipid and glucose 
metabolism. With a particular focus on the glycolytic enzyme Pyruvate kinase M2 (PKM2), 
which has been correlated also with the promotion and maintenance of the stemness traits, I 
focused my attention on the role of lipids as direct possible regulators of glycolysis and 
glycolytic enzymes. Medium and long-chain fatty acids are involved both in energy 
metabolism and in signalling pathways. Here, I show a new possible level of regulation, 
where fatty acids could act as allosteric regulators of PKM2. Using fatty-acid pull-down and 
in vitro binding assays, I demonstrate that PKM2 is able to directly interact with fatty acids. 
Particularly, my results suggest that it is the glycolytically inactive, dimeric form of PKM2 
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that preferentially interacts with FAs. To better dissect the functional implications of this 
regulation, finally I decided to characterize structurally the PKM2_K422E dimer mutant. 
Crystallization studies revealed a different conformation of the protein, compared to the wild 
type enzyme, that could correlate with the fatty acid binding capacity observed in my in vitro 
assays. Moreover, the structural characterization of the complex formed by PKM2_K422E 
and oleic acid is still under investigation.  
Although further investigations are required to deeply characterize the molecular mechanism 
underpinning the correlation between altered lipid metabolism, LDs accumulation and 
stemness traits, the possibility that targeting lipid metabolism and LDs formation could 
impact on tumorigenesis, opens important scenarios for the development of new therapeutic 
strategies. My findings pave the way for new possible mechanisms by which deregulated 
lipid metabolism can impact on cellular proliferation and cancer progression, via the 
regulation of one of the key metabolic players and glycolytic enzyme PKM2.      
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The research activities of my Ph.D. are dedicated to the dissection of the lipid metabolic role 
in breast cancer cells, with a particular emphasis on the implications in cancer stemness. 
Moreover, I focused my attention on the biochemical characterization of the role of lipids in 
Pyruvate kinase M2 regulation, a glycolytic gatekeeper enzyme involved in cancer onset and 
progression. Thus, this introductive chapter will illustrate the role of lipid metabolism in 
cancer stemness and in the metabolic reprogramming observed in cancer cells, with a 
particular focus on the interplay between lipid and glucose metabolism.      
 
1.1  Breast Cancer  
 
Breast cancer (BC) remains the most commonly diagnosed cancer among women worldwide 
(1), representing 24.5% of all new cancer cases diagnosed in 2020 (Figure 1.1). Despite 
increased early detection and improved therapeutic approaches, it also remains among the 
deadliest, with over 50,000 women succumbing to breast cancer every year. Highlighting 
the need for more effective diagnostic and therapeutic strategies. There are both genetic and 
environmental factors that can contribute to the development of breast cancer. Most notably, 
germline mutations in tumour suppressors BRCA1 and BRCA2 correlate with an increased 
risk of developing breast and ovarian cancers. In addition, epidemiological studies have 
suggested that obesity, alcohol consumption, use of contraceptives and hormone 












Figure 1.1 Percentage of new cases and mortality for the most common cancers in 2020 for women 
(1). 
 
BC is not one disease, but can be classed into at least four different subtypes with a range of 
histopathological features, molecular alterations and a highly variable response to 
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therapeutic treatments. In order to better classify the subtypes, histopathological criteria, 
including tumour grade, tumour stage, lymph node and metastasis, are the most widely used 
features and have both diagnostic and prognostic relevance (3). In addition, the status of 
hormone receptors like oestrogen receptor (ER), progesterone receptor (PR), epidermal 
growth factor receptor 2 (HER2/neu), are also used to stratify BC tumours. Their expression 
has been shown not only to have a prognostic value but also drive the choice of therapeutic 
regimen (4). Receptor expression levels are used to stratify breast cancer into four mains: 
luminal A (ER+, PR+, HER2-, lowKi-67), luminal B (ER+, PR+, HER2-/+, highKi-67), 
HER2 overexpressing (ER-, PR-, HER2+) and triple negative (ER-, PR-, HER2-) (5).  
Common molecular features of breast cancer include impaired DNA damage repair (DDR) 
resulting in genomic instability, mutations, chromosome rearrangements (6) and up-
regulation of signalling pathways that promote cellular growth and proliferation. Recent 
studies have also shed light on the correlation between oncogenic signalling and metabolic 
reprogramming in cancer cells.  
Metabolic reprogramming has been included among the hallmarks of cancer (7). The most 
studied metabolic pathways in cancer, such as aerobic glycolysis, nucleotide and fatty acids 
synthesis, and glutamine metabolism, are essential to support the higher cellular proliferation 
rates and growth. These pathways are regulated by oncogenic signalling networks and recent 
evidences have illustrated that, although all tumors undergo metabolic reprogramming, 
perhaps unsurprisingly, metabolic profiles differ among tumours. This observed 
heterogeneity also explains the varying efficacies of metabolism targeting therapies. For 
example, the use of antagonists of folate metabolism has been shown to highly effect most 
of the haematological cancers but not solid tumours (8). Moreover, also in the context of the 
same tumour, an intra-tumoral heterogeneity has been described that supports tumour 
evolution from primary site to the metastatic lesion, suggesting a scenario in which tumour 
metabolism is highly flexible and context-specific. In breast cancer dysregulated metabolism 
has been described both in untreated and in treatments-resistant populations. In most of the 
cases, the failure of the therapeutic approach is caused by the acquisition of secondary 
resistances (9). Resistant populations of cells have been shown to be, in part, characterized 
by a rewired metabolism (10, 11). This is particularly the case for HER2+ and triple negative 
breast cancers (12), which represent the BC subtypes most prone to development of 
therapeutic resistance (13, 14). The intense study of cancer metabolism has recently led to 
the recognition that cancer is not only a genetic disease but it also represents a metabolic 
disease (15). In this context, it becomes clear that a deep comprehension of the specific 
metabolic addictions observed in cancer cells is crucial, since they represent potentially 
important therapeutic targets.  
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1.2  Cellular metabolism as a hallmark of cancer 
 
Metabolism is a fairly recent addition to the list of factors required for the transition to 
malignancy. But, the study of cancer metabolism began nearly a century ago in 1927 with 
Otto Warburg’s seminal observation that tumour cells converted glucose to lactate in the 
presence of oxygen, and as such it represents one of the oldest fields of cancer biology (16). 
Although, Warburg hypothesized that this phenomenon was due to a respiratory impairment 
in mitochondria, further studies revealed that, in most of the cases, mitochondria were not 
defective in oxidative phosphorylation. Instead, the increased lactate production was the 
consequence of a general metabolic reprogramming required to sustain the increased energy 
requirements in cancer cells. Indeed, quiescent and proliferating cells differ considerably in 
their metabolism. The most prominent difference is the fate of the carbon sources (17). While 
in non-proliferating cells glucose is mostly converted into pyruvate and used in the 
tricarboxylic acid cycle (TCA cycle) to generate acetyl-CoA and ATP, in active proliferating 
cells glucose is used to sustain the pentose phosphate pathway, cholesterol and non-essential 
amino acid generation (18) (Figure 1.2).  
 
Figure 1.2. Glucose metabolism in quiescent and proliferating cells (17). 
 
Recently, it has become evident that tumour cells are characterized not only by aerobic 
glycolysis, but by increased uptake of glucose and amino acids along with dysregulation of 
nucleotide bio-synthesis and lipid metabolism. Collectively, this phenomenon is referred to 
as the “metabolic reprogramming” of cancer cells (19). The metabolic reprogramming that 
accompanies the transition to malignancy encompases nearly every aspect of cellular 
Science, 2009 
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metabolism. Given the breadth of the field I will now focus on reviewing the contributions 
of lipid and glucose metabolism in supporting tumour metabolism.  
 
1.3 The role of glycolytic enzymes in cancer 
 
The best characterized aspect of tumour metabolic reprogramming is the aerobic lactate 
production associated with increased glucose uptake referred to as aerobic glycolysis or the 
Warburg effect (20). The shuttling of glucose derived pyruvate into lactate production comes 
at the expense of efficient mitochondrial oxidative phosphorylation ATP production. To 
compensate for this, tumours uptake significantly higher amounts of glucose, thus providing 
not only important intermediary metabolites but also sufficient ATP.  
The increased flux of glucose through glycolysis is supported by the activity of three 
gatekeeper enzymes that catalyse three (nearly) irreversible reactions: Hexokinase, 



















Figure 1.3. The glycolytic pathway (Werner, Doenst et al. 2016). 
 
The first enzyme involved in the glycolytic pathway is Hexokinase (HK), that catalyses the 
conversion of glucose to glucose-6-phosphate (Figure 1.3), thus trapping it inside the cell. 
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There are five reported isoforms (I, II, III, IV, V) in human, and HKII overexpression has 
been observed in many tumours and linked with a more aggressive phenotype (21, 22). 
Moreover, in HKII knockout mice models of KRas-driven lung cancer and ErbB2-driven 
breast cancer, it was shown the key role of HKII for tumour development (23). 
In ovarian cancer HKII overexpression has been shown to be involved in the resistance to 
cisplatin treatments, by increasing cisplatin-induced autophagy mediated by ERK1/2 
phosphorylation (24). Moreover, in human glioblastoma it was shown that its deletion 
associates with a higher apoptotic index (25). The next glycolytic enzyme that catalyses an 
irreversible reaction, is Phosphofructokinase (PFK). PFK converts fructose-6-phosphate to 
fructose 1,6 bisphosphate (F-1,6-BP). It has been shown that the most important PFK 
activator is fructose-2,6-biphosphate (F-2,6-BP) that is generated by 6-phosphofrukto-2-
kinase/fructose-2,6-biphosphatase enzyme (PFKFB) (26) (Figure 1.4). Thus, creating a 
positive feedback mechanism: PFK activation is sustained by F-2,6-BP, that in this way 










Figure 1.4. Schematic representation of the first three reactions in glycolysis and the role of 
PFKFB. 
 
Pyruvate kinase (PK) catalyses the terminal reaction of the glycolytic cascade. In this step, 
PK enzyme is responsible for the conversion of phosphoenolpyruvate (PEP) to pyruvate, 
with the generation of ATP. In mammals, there are four different forms of Pyruvate Kinase 
(L, R, M1and M2) (27) encoded by two different genes: PKLR and PKM. By alternative 
splicing, PKL and PKR are produced from the PKLR gene transcripts, while PKM1 and 
PKM2 are produced by from PKM gene transcripts. The isoform expression is tissue-
specific, with PKL and PKR predominantly present in liver and red blood cells respectively; 
PKM1 is present in most adult tissues, while PKM2 is expressed by embryonic cells and 














accordingly. Importantly, it has been shown that in tumour cells PKM2 is highly expressed, 
while the expression of the other forms is negligible (29). 
The alternative spliced forms of PKM1 and PKM2, differ by only one exon. PKM1 includes 
exon 9 while excluding exon 10 and vice versa for PKM2 (Figure 1.5A). The two exons 
have the same length, but the sequence codifying for 56 amino acids differ by 23 residues 
(Figure 1.5B)  (30). The alternative splicing of the PKM mRNA is regulated by members 
of the family known as heterogeneous nuclear ribonucleoprotein family (hnRNP), 
particularly hnRNP1-2-I, that are able to bind the sites flanking exon 9, thus excluding it and 
promoting the exon 10 inclusion with the consequent PKM2 expression (31). Interestingly, 
in some cancers, the oncogene c-Myc has been shown to upregulate those hnRNP proteins, 















Figure 1.5. PKM2 gene and PKM2 aminoacidic sequence. (A) Alternative spliced forms of PKM1 
and PKM2 (33). (B) Aminoacidic sequence of human Pyruvate kinase M2. The underlined residues 
represent the 56 amino acids codified by exon 10 (27). 
 
 
1.3.1 Pyruvate kinase M2: a glycolytic gatekeeper deregulated in 
cancer 
 
While both the isozymes show the same catalytic activity, they are differently regulated. In 
fact, PKM1 is a constitutively active tetramer, while PKM2, thanks to the presence of the 




internal binding pocket necessary to host fructose-1,6-biphosphate (FBP), considered 
essential for the formation of the tetrameric structure (34). As a consequence of this, PKM2 
can switch from a less active dimer to a more active tetramer. Christofk and collaborators 
demonstrated in 2008 that in cancer cells in which PKM2 was depleted and substituted with 
PKM1 isoform, there was a metabolic switch from aerobic glycolysis to the physiological 
coupled glycolysis/TCA cycle. Moreover, PKM1 expressing cancer cells, compared to the 
ones expressing PKM2, were not able to develop tumours upon xenotransplantation into 
mice (35). These results highlight the important role of PKM2 in sustaining cancer cell 
metabolism, making it an interesting molecular target for cancer therapy.  
Through allosteric regulation PKM2 can switch from the highly active tetrameric form, able 
to sustain the production of pyruvate during glycolysis, to the lower active dimeric form 
(Figure 1.6). Despite being comprised of the same monomeric unit, the tetrameric and 
dimeric forms of PKM2 have very different functions. Compared to the dimer, the tetramer 
displays a higher affinity toward its substrate phosphoenolpyruvate and this correlates with 
the higher kinasic activity. Intriguingly, cytosolic association between the tetrameric form 
of PKM2 and glycolytic enzymes, such as hexokinase and enolase, has been reported, 
suggesting the role of metabolic factories in sustaining a processive glucose conversion to 
















Figure 1.6. Possible conformations of Pyruvate kinase M2 and allosteric regulators (37). FBP: 
Fructose 1-6 bisphosphate; SAICAR: PhosphoribosylAminoImidazolesuccinoCarboxamide; Ac: 
acetylation; P: phosphorylation; T3: 3,3’,5-triiodothyroxine; ATP: Adenosine triphosphate.   
EMBO Reports, 2016 
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In tumours PKM2 exists primarily in its dimeric state (38) (39), meanwhile forced 
expression of tetrameric PKM2 has been shown to suppress tumorigenesis (40). The 
development of a ELISA has allowed researchers to discriminate the dimeric form of PKM2 
in plasma from cancer patients (33). These studies suggested a role for dimeric PKM2 as a 
tumour marker for renal carcinoma and pancreatic cancer (41-43).  
The accumulation of the dimer leads to a lower conversion rate of PEP to pyruvate, and 
subsequently to the accumulation of glycolytic intermediates (34) leading to increased flux 
through anabolic pathways such as the pentose-phosphate pathway (PPP) that sustains the 
growth and the proliferation of tumour cells (44, 45). For example, the production of ribose-
5-phosphate, necessary for nucleic acid biosynthesis, depends upon glucose-6-phosphate 
flux through the pentose-phosphate pathway (PPP). Another important metabolite generated 
by PPP is nicotinamide adenine dinucleotide phosphate (NADPH), an important cofactor 
and electron donor essential for providing the reducing power to anabolic pathways and for 
preventing oxidative stress (46). Instead, another component of the glycolytic pathway, 3-
phosphoglycerate, is an essential precursor for the biosynthesis of amino acids glycine and 
serine, whose synthesis was shown to be essential in breast and lung cancer (47, 48).            
In addition to its well characterized role in glycolysis, there is mounting evidence to 
suggesting a non-canonical function of PKM2 in cancer cells. Dimeric PKM2 was recently 
reported to localize to the nucleus where it was shown to act as a protein kinase (49-51). 
Upon translocation into the nucleus, it has been proposed that PKM2 is able to phosphorylate 
multiple proteins including ERK1/2, STAT3, and histone H3 (45, 52, 53). STAT3 
phosphorylation PKM2-mediated has been linked with tumorigenesis in anaplastic large cell 
lymphomas (54) and with enhanced cell migration in colon-rectal cancer (55). The role of 
PKM2 in tumorigenesis has been also shown in brain tumours, where the phosphorylation 
of another substrate, histone H3 at Threonine 11 residue, mediated by PKM2, leads to the 
activation of cyclin D1 and c-Myc, highlighting the role of the dimeric nuclear form of 
PKM2 as a novel regulator of cell-cycle progression and proliferation (53). 
Additionally, nuclear PKM2 was also shown to regulate ß-catenin, Oct4 and HIF-1. Indeed, 
in glioma cells PKM2 nuclear translocation, regulated by the epidermal growth factor 
receptor (EGFR), leads to the activation of beta-catenin with the consequent expression of 
cyclin D1. This mechanism has been correlated with glioma malignancy, since PKM2-
mediated beta-catenin transactivation has an impact on cell proliferation and tumorigenesis 
(56). In addition to this, PKM2 has been described as a novel interactor of Oct-4 transcription 
factor, whose trans-activation is important for the maintenance of the pluripotent state of 
stem cells (57). Recently, PKM2 transcription has been shown to be activated by the 
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hypoxia-inducible factor 1 (HIF-1). Moreover, once expressed, PKM2 contributes to the 
activation of HIF-1 factor, creating a positive feedback mechanism that sustains glucose 
metabolism reprogramming, angiogenesis and cancer progression (58).      
Overall, the glycolytic and non-glycolytic protein kinase roles of PKM2 have been shown 
to play key roles in regulating the survival, pluripotency and the metabolic reprogramming 
observed in cancer cells.     
 
1.3.2 PKM2 allosteric regulation in cancer 
 
The allosteric regulation of PKM2 modulates the multimerization state of the protein (59). 
Glycolytic intermediate, fructose 1,6-biphosphate (FBP), was one of the first regulators 
described to induce the tetrameric active form of PKM2, and it remains the most significant, 
tying PKM2 activity to glucose availability (60). In vitro studies performed toward the 
middle and the end of the last century have shown that PKM2 activity could be also 
modulated by other macromolecules, such as amino acids or lipids (61-63). More recent 
work has identified serine as another allosteric activator of PKM2 able to induce the 
tetramerization of the protein, and has shown that serine deprivation correlates with a 
reduced activity of the enzyme (64). An additional PKM2 activator is an intermediate of the 
de novo nucleotide synthesis, SAICAR (succinylaminoimidazolecarboxamideribose-5’-
phosphate). SAICAR was shown to induce PKM2 activity promoting cancer cell survival 
also under glucose deprivation (38) (Figure 1.6). In addition, several negative allosteric 
regulators of PKM2 have been described. Alanine, phenylalanine and tryptophan have been 
shown to inhibit tetramerization hence stabilizing the dimeric form or the so-called T-state, 
which represents an inactive tetramer (65).  
Multiple post-translational modifications have been associated with the inhibition of PKM2 
activity. For example, fibroblast growth factor receptor 1 (FGFR-1) can phosphorylate 
PKM2 on Tyr105 impeding FBP binding and hence the activation of the enzyme (66). In 
cancer cells, the oxidation of Cys358 mediated by increased Reactive Oxygen Species 
(ROS), inhibits PKM2 activity (67). This allows for up-regulation of the ROS detoxification 
process thanks to the boosted pentose phosphate pathway, and it is used by the tumour cells 
to resist in more hostile environments. The inhibition of PKM2 can also be mediated by 
acetylation. Indeed, as shown by Lei and collaborators, the acetylation of Lys433 leads to a 
lower PKM2 affinity towards its allosteric activator FBP and promotes PKM2 nuclear 
translocation (50).  Furthermore, high glucose levels stimulate PKM2 acetylation at Lys305; 
this post-translational modification has been associated with a decreased PKM2 activity and 
with an increased protein degradation through a chaperone-mediated autophagic process 
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(68). In addition to this, PKM2 acetylation mimic mutant Lysine-305-Glutamine (K305Q) 
stably expressed in lung cancer cells, induces a massive accumulation of glycolytic 
intermediates and NADPH, and correlates with a higher proliferative phenotype of cancer 
cells, suggesting again the importance of PKM2 regulation in the cellular microenvironment.  
 
1.4 The glucose-fatty acid cycle 
 
Glycolytic enzymes are key players in the cellular metabolism. Several studies have 
highlighted the role of free fatty acids and lipids as regulators of glycolytic enzymes, such 
as phosphofructokinase and pyruvate kinase (69, 70), connecting the two main cellular 
pathways involved in energy production. The first description of the role of lipids in the 
regulation of glucose metabolism was reported in the 1960s. Indeed, in 1963 Philip Randle 
showed for the first time that there existed a hormone independent cross-talk between 
glucose metabolism and fatty acid oxidation (71). This interplay, later named “Randle 
Cycle” or “glucose-fatty acid cycle”, describes a mechanism by which glucose metabolism 
is inhibited when high levels of fatty acids are available and, vice versa, fatty acid oxidation 
is inhibited when glycolysis proceeds with high processivity thanks to the accumulation of 
intra-cellular glucose. These observations generated interest in the field and some years later 
new studies emerged highlighting the role of short and long chain fatty acids in the inhibition 
of pyruvate kinase enzyme (72). Since then, many studies tried to better characterize, from 
a molecular point of view, the relationship between glucose and fatty acids usage. Some 
examples are the description of the role of citrate as allosteric inhibitor of 
phosphofructokinase that has been shown in heart and liver (73), and the role of pyruvate 
dehydrogenase (PDH) described more recently as a key regulator of glucose and lipid 
homeostasis (74) in in vivo studies of obese mice. Although, further studies are still required 
to better elucidate all the molecular mechanisms involved in the direct regulation of this 
complex network.  
Despite the initial studies described above were focused on the role of glucose-fatty acid 
interplay in normal tissues, an antagonism between fatty acids oxidation and glycolysis has 
been described in many cancers. Indeed, the switch from the catabolic to the anabolic 
metabolism observed in cancer cells, represents part of the execution of the Randle cycle.  
In non-Hodgkin lymphomas, a dysregulation of both fatty acids biosynthesis and glycolysis 
has been described in the context of a more general metabolic alteration, with human non-
Hodgkin lymphomas B-cells showing an up-regulation of both fatty acid synthesis and the 
glycolytic flux in the comparison with primary B cells (75). Colon-rectal cancer and 
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glioblastoma are instead considered tumors highly dependent on glucose to sustain their 
proliferation but, while this description pretty well defines the primary tumor, in the 
metastatic lesions both tumors show a switch from glycolysis to fatty acid oxidation to fulfill 
their energy requirements and to survive in hostile microenvironments (76, 77). An 
important aspect to consider is that not all the internalized glucose is used to generate 
pyruvate; indeed, glucose is often re-directed to the pentose-phosphate pathway (PPP) where 
sustains nucleotide synthesis and NADPH production. Thus, even if the concept of cancer 
cells relying on glucose metabolism more than fatty acid oxidation seems to be 
counterintuitive, in the reality it is not about ATP generation but it is about the increased 
anabolic metabolism able to sustain cell growth.  
Cancer metabolism is highly plastic. The regulation of the cellular metabolic behavior 
mediated by the nutrient accessibility, firstly described by Randle, can be important for the 
generation of novel therapeutic strategies. Deciphering the metabolic connections between 
the glycolytic pathway and fatty acids metabolism can inspire new approaches to better 
tackle cancer cells.     
 
 
1.5 Dysregulated lipid metabolism in cancer  
 
Lipids play an essential role within the cancer cell functioning as a component of cellular 
membranes, carbon sources, and as signalling molecules. As anticipated before, in order to 
fulfil their lipid requirements, cancer cells reprogram their lipid metabolism to increase both 
lipid uptake and de novo fatty acid synthesis. In healthy cells, lipid uptake from the 
bloodstream usually satisfies the cells demands for fatty acids. In contrast, in cancer cells, 
uptake of exogenous fatty acids is not sufficient to meet their needs and requires 
supplementation, which is achieved through upregulation of endogenous FA biosynthesis. 
This is realized by dysregulation of lipogenic enzymes, including Fatty Acid Synthase 
(FASN), the enzyme that catalyses the production of Palmitate starting from Acetyl-CoA 
and Malonyl-CoA. Many studies have reported the overexpression of FASN in multiple 
cancers, including breast cancer (78), prostate cancer (79), glioma (80) and melanoma (81). 
Targeting of FASN has been shown to be an effective anti-tumor strategy suggesting that de 
novo fatty acid biosynthesis plays a key role in sustaining cancer progression and survival 
(82) .    
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An important role in cancer lipogenesis is also played by the Acetyl CoA carboxylase (ACC) 
and stearoyl CoA desaturase 1 (SCD1) enzymes. The lipogenic pathway consists in the 
production of de novo fatty acids starting from acetyl-CoA, that is generated after glycolysis 
and the mitochondrial tricarboxylic acid cycle (TCA). Acetyl-CoA is converted into 
malonyl-CoA by ACC enzyme, and then malonyl-CoA with acetyl-CoA forms palmitic acid 
in a reaction catalysed by FASN enzyme. Afterwards, palmitic acid is transformed in stearic 
acid by the elongase ELOVL6 (83). The final products palmitoleoyl-CoA and oleoyl-CoA, 
generated from palmitoyl-CoA and stearoyl-CoA in a reaction catalysed by SCD1, are 
transformed in triglycerides or phospholipids for membrane generation or storage (Figure 
1.7).  
 
Figure 1.7. Fatty acids generation in cancer cells rely on de novo lipogenesis and exogenous 
uptake (84, 85). 
 
 
ACC, FASN and SCD1 expression is regulated by signalling pathways. Among them, two 
of the most essential key regulators are: SREBP-1, sterol regulatory element-binding protein,  
important for lipid and cholesterol homeostasis, and mTOR, a major regulator of growth (86, 
87). SREBP-1 is the most important transcription factor involved in the gene expression of 
lipogenic genes, such as ACC, FASN and SCD1. In cancer, the epidermal growth factor 
(EGF) activates the PI3-kinase/Akt pathway leading to the phosphorylation and activation 
of SREBP-1 (88). In glioblastoma, in particular, SREBP-1 has been correlated with tumor 
Br J Cancer, 2020 
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growth and therapeutic resistance (89, 90). In SREBP-1 activation can also be involved the 
mechanistic target of rapamycin (mTOR).  
mTOR is a Serine/Threonine kinase and is the catalytic subunit of two protein complexes 
mTORC1 and mTORC2 (91). The PI3K/AKT/mTORC1 dependent pathway strongly 
regulates SREBP1 activity, by inducing the activation of the transcription factor with the 
consequent expression of lipogenic genes (92). In addition, also mTORC2 is an important 
regulator of lipid metabolism. Upon SREBP1 activation, mTORC2 up-regulates de novo 
synthesis of glycerophospholipids and sphingolipids, and its overexpression has been 
associated with tumorigenesis in hepato-carcinoma (93).                  
Beyond synthesis cancer cells have been shown to uptake exogenous fatty acids.  One of the 
major players in the uptake of exogenous fatty acid is CD36 receptor, cluster of 
differentiation 36, also known as Fatty Acid Translocase (FAT). Interestingly, CD36 
overexpression has been associated with epithelial-mesenchymal transition in hepato-
carcinoma (94) and with tumour dissemination and invasion in ovarian cancer (95). In ER+ 
breast cancer patients, high circulating free fatty acid levels and high CD36 expression 
correlate with tumor progression and aggressiveness by activating oestrogen receptors and 
mTOR signalling pathway (96).   
It is broadly accepted that fatty acids, together with cholesterol, are fundamental to cancer 
cells for membrane biosynthesis and fluidity, and for providing energy under stressful 
conditions. One of the advantages conferred by de novo fatty acid synthesis is the generation 
of saturated fatty acids. Indeed, the higher level of membrane saturation in cancer cells has 
been correlated with a lower vulnerability to therapeutic drugs inducing oxidative stress (97). 
Saturated fatty acids are more stable than the unsaturated or polyunsaturated ones, since 
double bonds are usually subjected to peroxidation induced by reactive oxygen species 
(ROS). This phenotype has been mostly observed in primary tumors, while, epithelia to 
mesenchymal transition induces the acquisition of a more fluid membrane that sustains the 
cellular migration towards distant organs. Moreover, fatty acids are also necessary to form 
bioactive lipids that are essential secondary messengers that sustain signalling pathways 
involved in cell proliferation and survival. For example, phosphatidyl-inositol(3,4,5)-P3, via 
AKT, is involved in the activation of mTORC1 and mTORC2 that, as described before, are 
master regulators of cell proliferation and survival (98). Together with 
phosphatidylinositols, fatty acids are also used as precursors of another class of bioactive 
lipids, eicosanoids. In fact, arachidonic acid is the key precursor of different eicosanoids 
such as prostaglandins and leukotrienes that have been associated with pro-tumorigenic 
events (99). Taken together these evidences suggest that dysregulated lipid metabolism is 
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not only necessary to support proliferation, but that increased lipid uptake and lipogenesis 
impart upon the cells a more aggressive phenotype.  
 
1.5.1 Lipid droplets 
 
Cancer lipogenesis contributes to the accumulation of neutral lipids and sterol esters that are 
stored within lipid droplets (LDs), the lipid cytosolic reservoir of the cells. The storage of 
neutral lipids inside these organelles protects cells from lipotoxicity, as well as functioning 
as an energy reserve (100). LDs have been described as important players for both cancer 
initiation and progression (101). Their accumulation in cancer cells relies upon a 
combinatorial effect of upregulated lipid uptake, increased fatty acid synthesis, and de-
regulated lipolysis.  
Lipid droplets (LDs) were long considered an inert organelle devoted to fat storage. 
Recently, it has become clear that their role is more complex and that they contribute to the 
regulation of multiple cellular processes, including cell signalling, inflammation, lipid 
metabolism and membrane biosynthesis (102). Lipid droplets are composed of a 
hydrophobic core of neutral lipids, containing primarily triacylglycerol (TAG) and 
cholesterol esters (CE), surrounded by a phospholipid monolayer. In addition to the lipid 













Figure 1.8. Lipid droplet structure and composition (105). 
 
Lipid droplet size and composition are strictly regulated according to the cell type and to the 
metabolic state of the cells. LDs formation has been extensively studied and multiple models 
of lipid droplet biogenesis have been proposed (106-108). Although many of the details 
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remain unknown, the most widely accepted model describes a budding process of the 
endoplasmic reticulum (ER) towards the cytosolic environment (109). In this model, the 
biogenesis starts with the synthesis of neutral lipids, in particular triacylglycerols and stearyl 
esters (SE) in the ER, and their accumulation leads to the formation of a lens within the ER 



















Figure 1.9. Lipid droplets biogenesis (105). 
 
 
These neutral lipid lens extrude as buds from the Endoplasmic Reticulum membrane towards 
the cytosol at defined ER domains, where protein and lipid composition play an important 
role (111). It has also been suggested that LDs budding and size is influenced by chemical 
and physical membrane parameters, such as intrinsic curvature (112), ER phospholipid 
content and surface tension (113). 
 
1.5.2 Lipid Droplets Accumulate in Tumours from Diverse Tissue Types 
 
LDs accumulation has been reported in several tumours, including colon-rectal cancer (114, 
115) glioblastoma (116), melanoma (117) and breast cancer (118-120). Their accumulation 
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in cancer cells is associated with cancer onset and progression. LDs formation, driven by 
TGFb signalling, has also been associated with tumour acidosis, epithelial-mesenchymal 
transition (EMT) and mesenchymal-epithelial transition (TEM) in invasive phenotypes of 
cancer cell lines (121). Recently, it has been shown that epithelial and mesenchymal breast 
cancer cells are characterized by a different lipid profile. In particular, epithelial cells show 
an elevated fatty acid synthesis and mono-unsaturated lipid, while mesenchymal cells 
instead present a down-regulated lipogenic profile, together with an increased expression of 
genes necessary for LD formation (122). Although, the role of LDs in metastatic disease is 
still not properly characterized, accumulating evidence sustain that their accumulation in 
primary tumour cells act as a prognostic marker for metastatic potential (123). 
A correlation between Perilipin 2 (PLIN2) expression, one of the most important LDs 
associated proteins, and tumour aggressiveness has been demonstrated. For example, in 
gastric cancer the overexpression of PLIN2 is linked with a malignant phenotype (124); 
similar results were previously shown in lung adenocarcinoma from Zhang and colleagues 
(125). In melanoma and in renal carcinoma, the overexpression of Perilipin 3, another 
member of the Perilipin family, was reported to correlate with a poor prognosis (126, 127). 
More in general, a negative correlation between PLIN protein expression and relapse free 
survival in patients was also shown in lung and renal carcinoma (128, 129). Considering the 
important role in lipid metabolism regulation, lipid droplets are now considered key 
organelles in many cancers. Unfortunately, while many studies have demonstrated a 
correlation between LD accumulation and a tumorigenic phenotype, the molecular 
mechanisms behind this phenomenon remain poorly investigated. Intriguingly they may 
represent an interest target for therapeutic intervention. It is known that their breakdown can 
be capitulated upon to protect cells in hostile conditions. Indeed, fatty acids deriving from 
lipid droplets are usually used to sustain cell proliferation in exogenous lipids deprivation 
and starvation (130). This process is regulated by AMP kinase, which activates lipid droplets 
re-localization to mitochondria and consequently fatty acid oxidation (131). Very recently, 
LDs have been also associated with cancer therapeutic resistance. Their hydrophobic pocket 
allows them to be an accumulation site for lipophilic drugs, thus decreasing treatment 
efficacy (132, 133). Due to the emerging evidences of LDs accumulation in cancer, they are 
now considered crucial components of the tumoral reprogrammed lipid metabolism and 






1.6 Lipid droplets and breast cancer stem cells 
 
1.6.1 Cancer stem cells origin and biomarkers  
 
Cancer stem cells (CSC) are defined as a niche of cells responsible for tumour initiation and 
maintenance. These cells are characterized by “stem” traits such as multipotent 
differentiation and self-renewal capacity. Since they are usually not responsive to cancer 
treatments, they represent, in most of the cases, the main cause of therapeutic treatment 
failure, tumour relapse and metastatic dissemination (134, 135). Although, the origin of CSC 
is still debated there are two main hypotheses for the mechanism behind their emergence: 
(1) they arise from normal stem cells that have acquired oncogenic mutations; (2) they derive 
from cancer cells that have undergone a de-differentiation processes leading to the 
acquisition of stem properties (Figure 1.10).  Due to their pivotal role in tumorigenesis, the 















Figure 1.10. Cancer stem cells origins (136). 
 
The identification of this small sub-population of cells usually relies on particular surface 
biomarkers that in some cases are shared by different cancer types. In breast cancer, several 
surface markers have been described, with several belonging to the Cluster of Differentiation 
(CD) family. One of the most frequently used is CD44, whose expression has been 
associated with self-renewal capacity and metastasis (137, 138). This marker shows both a 
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diagnostic and a therapeutic value (139). Another important marker described in breast 
cancer stem cells is CD133, which correlates with a poor prognosis (140). Its expression is 
usually associated with N-Cadherin and EpCAM expression (141, 142) whom recently were 
described to be associated with improved metastatic capacity (143).  Yet, not all CD44 high 
cells are CSC. Therefore, in order to distinguish and isolate CSC it is a common practice to 
use a combination of surface markers together with intra-cellular proteins.   
Together with the surface markers, several transcription factors have been associated with 
stemness properties. Among them we find Oct-3/4, Sox2, Notch and Nanog whose activation 
is correlated with higher expression of self-renewal genes and a down-regulation of 
differentiation genes (144, 145). In HER2 positive breast cancer patients, a correlation was 
observed between Oct4, Sox2 and Nanog overexpression and a worse prognosis (146).    
Cancer stem cells share many features with normal stem cells, making their identification 
and isolation a complex task. In order to isolate CSC, several in vitro assays have been 
developed combining well-characterized stemness properties with cancer features. Among 
them we can find tumor initiating and self-renewal capacity in non-adherent conditions, 
studied through sphere-forming assays (147); the dye exclusion capacity of CSC due to their 
up-regulation of many transporters, analysed by the use of nuclear dyes like Hoechst (148); 
the expression of specific cell surface markers and genes, found to be key regulators of 
stemness (149) and known to be overexpressed in many cancers, analysed by FACS. 
However, the lack of specific in vivo assays still represents a huge problem in the field, since 
they could improve our capability to identify and isolate these cells. A better characterization 
of this small sub-population of cells, which would allow us to selectively target these cells 
in clinics, is urgently needed.     
 
1.6.2 Cancer stem cells metabolism and LDs  
               
Recent evidence highlighting metabolic changes between normal stem cells and cancer stem 
cells, suggests metabolic profiling as a possible means to distinguish this sub-population of 
cells (150). For this reason, CSC metabolism is an active field of research that is starting to 
yield significant insights into the cancer cell biology field (151). Alterations of both glucose 
and lipid metabolism in CSC have been described (152). Yet, emerging evidence suggests 
that the metabolic profile of CSC could vary between tumours. Hepatocarcinoma cancer 
stem cells which are characterized by CD133 positivity have a glycolytic addiction, with 
inhibition of glycolytic enzymes leading to the down-regulation of specific stemness 
markers, like Sox2 and Oct4 (153), and spheroids-forming capacity in vitro (154). 
Furthermore, breast cancer cells which are characterized by CD44+/CD24-/EPCAM+ show 
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a metabolic switch from oxidative phosphorylation to aerobic glycolysis that sustains the 
anabolic growth and is involved in a more general metabolic reprogramming, including 
higher ROS production, increased glucose uptake and oxygen consumption (155). The list 
of tumours showing that CSC, in comparison to the differentiated tumour cells, are 
characterized by a more glycolytic-based metabolism is growing. Indeed, it has been already 
described in glioblastoma (156), colon-rectal cancer (157), ovarian cancer (158) and 
nasopharyngeal carcinoma (159).   
Instead, other findings, have reported a more OXPHOS dependency of CSC to fulfil their 
needs and to sustain their self-renewal capacity. This has been described for example in 
pancreatic ductal carcinoma, where CD133+ CSC up-regulate mitochondrial biogenesis to 
adapt their metabolism to their energetic requirements (160). Also, in glioblastoma CSC 
have been shown a certain dependency on OXPHOS for the maintenance of the stemness 
traits (161). In leukaemia, CSC which are CD34+/CD38- are able to reprogram their 
metabolism going from an OXPHOS-dependent when in a dormancy state, to a glycolytic-
dependent metabolic profile when in a proliferative state. This switch is regulated by the 
apoptosis regulator BCL-2 that is involved in the up-regulation of OXPHOS (162). As 
shown above for glioblastoma, it seems that the same tumour can be characterized by 
different metabolic dependencies. Hence, emerging studies are now suggesting that CSC 
metabolic profile may depend on the cellular proliferative state, the tissue of origin and the 
metastatic preferential site. Actually, CSC allocated in hypoxic alcoves, like hematopoietic 
stem cells in the bone marrow, are truly dependent on aerobic glycolysis if compared to other 
tumor types (163).                     
In addition, a de-regulation of lipid metabolism has also been described in association with 
CSC phenotype. Low membrane fluidity, that is associated with a lower level of lipid 
unsaturation, correlates with a down-regulation of the stemness capacity and metastatic 
disease in breast cancer (164). Nevertheless, both leukaemia and hepatocarcinoma stem cells 
showed an addiction to fatty acid oxidation (FAO) that in the case of hepato-cells relies on 
the NANOG-mediated hyper-activation of FAO genes (165, 166). The increased FAO could 
also link with the observation that in leukaemia FAO is uncoupled from ATP generation, 
leading to continuous fatty acid biosynthesis (167), sustained also by FASN over-expression 
(168). FASN overexpression seems to play a key role in maintaining tumour-forming 
capacity and stemness traits also in glioma CSC. Indeed, in these cells, FASN inhibition led 
to the reduction of CD133 stem marker expression and to a lower invasiveness, while 
increasing the expression of the differentiation marker Glial Fibrillary Acidic Protein 
(GFAP) (169). 
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Another key player in lipid metabolism that has been associated with CSC is stearoyl-CoA 
desaturase 1 (SCD-1). SCD-1 overexpression has been reported both in lung CSC, where it 
stabilizes the nuclear localization of YAP/TAZ complex (170, 171), and in ovarian cancer, 
where it correlates with an higher tumorigenic capacity and its over-expression is regulated 
by the nuclear factor NF-kB (172). As described previously, SCD1 catalyses the conversion 
of saturated fatty acids to Mono-Unsaturated Fatty Acids (MUFAs), precursors of many 
lipids like triglycerides, diacylglycerols and cholesterol esters.  
The up-regulation of lipid biosynthesis pathways may lead to the accumulation of lipid 
droplets, since excess lipids are stored in these organelles. Several studies have begun to link 
lipid droplet accumulation with stemness traits and invasion in colon cancer, ovarian cancer 
(172), glioblastoma (173) and prostate cancer (174). In colon cancer, a correlation between 
LD content and tumorigenic characteristics has been shown to be associated with the up-
regulation of CD133 and the Wnt/beta catenin pathway (175). In some cases, it was observed 
that the accumulation of LD was employed by CSC as a reservoir of energy in form of lipids 
(176); in that case, the inhibition of lipolysis, led CSC to death. In this scenario, it appears 
clear that a better understanding of CSC metabolism can allow us to identify new strategies 
for evaluating CSC growth and target their peculiar features, thus preventing tumour relapses 




















1.7 Aims of my Ph.D. project 
 
Breast cancer related death is usually caused by tumour relapses and metastasis 
development. The metastatic disease can rise from residual cancer stem cells (CSC) resistant 
to the therapeutic treatments (177). In particular, those sub-populations of cells accumulate 
lipid droplets (LD). Recently, it has become clear that lipid droplets play a role in the 
regulation of a variety of cellular processes, including cell signalling, inflammation, lipid 
metabolism and membrane biosynthesis (102). Interestingly, LD accumulation has been 
frequently observed in a variety of cancer types (116) (114). Consistent with the cancer stem 
cell theory, CSC have a role in both origin and tumour progression, as well as in tumour 
relapses. Thus, it becomes crucial to better characterize and target this population of cells 
during the diagnostic phase and the therapeutic approach (178). Unfortunately, to date, we 
still miss a detailed characterization of CSC in breast cancer and this is mainly due to the 
lack of specific markers. While a number of studies have shown the role of lipid metabolism 
in cancer stemness, the presence of lipid droplets in breast cancer stem cells has been never 
investigated. Based on these considerations, the first aim of my Ph.D. project was to: 
 
1. Assess the contribution of lipid droplets to CSC maintenance and their correlation 
with tumour onset, with the hope of revealing new therapeutic targets 
 
The accumulation of lipid droplets is part of a more general lipid metabolic reprogramming 
observed in breast cancer patients (179). Despite being a more recent concept compared to 
the Warburg effect, the importance of lipids in cancer metabolism has been fully recognized. 
The role of lipids as modulators of the activity and function of proteins and enzymes attracted 
scientists long time ago. Moreover, a decreased activity of some glycolytic enzymes, such 
as phosphofructokinase (PFK) and pyruvate kinase (PK), was also described caused by the 
increased levels of citrate (69, 180). The inhibition of glycolytic enzymes activity means a 
shift of the cellular metabolism from catabolism to anabolism, mechanism that is very often 
observed in cancer cells. Despite the increased interest in the field, there are still many gaps 
in the understanding this aspect that need to be covered. The more recent technologies allow 
us to better characterize the interplay of the two main cellular pathway, lipid and glucose 
metabolic pathways. Thus, the second aim of my Ph.D. project was to: 
   
2. Dissect the biochemical interplay between glucose and lipid metabolism in breast 
cancer cells 










Chapter II  







































2.1 Media  
The growth media used for Escherichia Coli cultures were: Luria-Bertani (LB) broth 
containing Peptone 140, Yeast extract and Sodium chloride; Terrific Broth (TB) containing 
Yeast extract, Tryptone, Potassium hydrogen phosphate, Potassium dihydrogen phosphate 
and glycerol. TB media for Pyruvate kinase M2 purification was supplemented with 
kanamycin antibiotic 50 µg/ml. 
 
2.2 Cell Lines and Culture Conditions 
In this study were used the following human breast cancer cell lines: BT474, MCF7, T47D, 
MDA-MB 231, BT549, SUM-190, ZR-75-1, MDA-MB-468, SKBR3, and MDA-MB-
453cells. BT474, MDA-MB-453 and SKBR3 cells were purchased from DSMZ; MCF7, 
T47D, MDA-MB 231, MDA-MB-468 and BT549 were purchased from the National Cancer 
Institute (NCI); SUM-190 cells were purchased from Asterand; ZR-75-1 cells were 
purchased from ATCC. All the cell lines were maintained in Roswell Park Memorial 
Institute 1640 RPMI (Lonza) supplemented with 10% fetal bovine serum and 2 mM L-
Glutamine and cultured at 37˚C in a humidified atmosphere 5% CO2 incubator.  
 
2.3 Nile Red staining and Lipid droplets quantification analysis 
The Nile Red staining was performed as previously reported (181) . Briefly, Nile red 
(Invitrogen, N1142) stock solution was made in DMSO at a concentration of 1 mg/ml.  For 
the cellular staining cells were seeded on poly-lysine coated coverslips and then fixed in 
Paraformaldehyde 4% for 15 minutes. After washing, the cells were incubated for 10 
minutes in Nile red (1 µl of 1 mg/ml Nile Red stock in 10 ml of 150 mM NaCl) protected 
from light. Nuclei were stained using Dapi and finally coverslips were mounted onto glass 
slides. For the Lipid droplets analysis quantification, a Fiji plug-in (developed by Martini 
E.) was used. Briefly, after manually delineating a ROI around the cells, the plugin identified 
lipid droplets using the ImageJ’s Find Maxima2 algorithm on the maximum projection 
image after background removal (using the rolling ball algorithm3) and noise reduction (with 
a median filter). 
 
2.4 RNA extraction and quantitative RT-PCR Analysis 
In order to perform the RT-PCR analysis, total RNA was first isolated using Trizol-
Chloroform extraction with TRIzol reagent (Life Technologies) and Chloroform (Carlo 
Erba). For the cells collected following cell sorting, RNA was extracted using the RNeasy 
Mini Kit (Qiagen). After the extraction, the RNA was quantified by NanoDrop to assess both 
concentration and quality. Reverse transcription was performed using the SuperScript III 
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Reverse Transcriptase kit (Invitrogen). Gene expression was analyzed using the TaqMan 
Gene expression analysis. Sample were amplified with primers for each gene and Actin B 
was used as housekeeping. The list of the assay ID used is shown in Table 2. 
 
2.5 Mammospheres formation assay from cell lines 
The primary mammospheres were produced as previously described (182). The 
mammospheres media used in this assay was DMEM-F12 (Biowest) supplemented with B27 
supplement (Invitrogen) and EGF (20 ng/ml; Vinci Biochem). To prepare non-adherent 
plates, standard 6-well plates were coated with 1ml of 1% agarose solution in PBS. To 
produce the 1% agarose solution agarose powder was dissolved in PBS and autoclaved. 
Briefly, cells were centrifuged at 580 g for 2 minutes and resuspended in 2 ml PBS. To avoid 
cellular aggregates, a 22 G needle was used to syringe the cell suspension. We found out 
that 104 cells/well was a good seeding density for our cell lines. Cells were plated and 
incubated in a 5% CO2 humidified incubator at 37˚C. After 5 days, all mammospheres larger 
than 50 µm were counted and the Mammospheres Formation Efficiency (MFE) % was 
calculated using the equation MFE(%)= (number of mammospheres per well/total number 
of cells seeded for well)x100.   
 
2.6 BODIPY for staining and Fluorescence-Activated Cell Sorting 
BODIPY™ 500/510 C1, C12 (4,4-Difluoro-5-Methyl-4-Bora-3a,4a-Diaza-s-Indacene-3-
Dodecanoic Acid) (Molecular Probes) stock solution (1mg/ml) was prepared in ethanol and 
kept at -20˚C until used. For the cellular staining cells were seeded on poly-lysine coated 
coverslips and incubated overnight with 1 µg/ml bodipy in the media. The day after cells 
were fixed in Paraformaldehyde 4% for 15 minutes. After washing, nuclei were stained using 
Dapi and finally coverslips were mounted onto glass slides.  
For FACS sorting, the cells were incubated with 1 ug/ml BODIPY™, following an overnight 
incubation, they were washed twice, trypsinized, resuspended in PBS 2% FBS 0.3% 
Gentamycin and sorted on a MoFlo Astrios Beckman Coulter (Beckman).   
 
2.7 Assessment of lipid droplet content using CD44/CD24 stem cell markers 
MDA-MB-231 and BT474 cell lines were cultured in 6-well plate wells (Falcon, Ref no. 
353046). On the night prior to FACS analysis cells were treated with BODIPY™ 500/510 
C1, C12, as described in 2.6. Following incubation with BODIPYTM 500/510 C1, C12 the 
cells were harvested and incubated in 500µl of a 1X D-PBS, 5% BSA, blocking buffer for 
45 min at room temperature. The cells were then stained with Alexa Fluor® 647 Mouse 
Anti-Human CD24 and CD44-VioBlue® mouse anti-human CD44 for 30min on ice 
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(antibodies details are listed in Table 1). The antibody concentrations recommended on the 
accompanying data sheets were used for the stain. Following staining the cells were pelleted 
and washed three times with a 1X D-PBS, 1%BSA solution, prior to resuspension in a 1% 
FBS, 1X D-PBS solution. The FACS was conducted using the Attune NxT (Thermofisher 
Scientific). FACS data depicted represents analysis done on single, propidium iodide 
negative, cell population. FlowJo Version 10.4.2 was used for the analysis.      
 
2.8 5-(Tetradecyloxy)-2-furoic acid (TOFA) Treatments 
TOFA (Sigma-Aldrich T6575) was resuspended in two milliliters of DMSO and stored at -
20˚C. Experiments in which cells were treated with TOFA, unless otherwise specified, were 
cultured in the presence of 10 uM TOFA in their normal growth media for forty-eight hours 
prior to initiating measurements or assays. 
 
2.9 FACS of fatty acid loaded and TOFA treated cells 
FACS analysis of fatty acid loaded cells was done by culturing cells to 30-40% confluence. 
The normal growth media was then spiked with 100 uM Oleic acid (Sigma-Aldrich 01383) 
and 50 uM Palmitic acid (Sigma-Aldrich P5585) for forty-eight hours. Twelve hours prior 
to FACS cells were treated with Bodipy at 1ug/ml. Immediately before FACS, cells were 
then trypsinized and spin at 1200rpm for five minutes. The pellet was gently washed with 
D-PBS and resuspended in D-PBS containing 2%, 0.22um filtered, FBS. FACS was 
conducted using Attune NxT (Thermofisher Scientific). FACS data depicted represents 
analysis done on single, DAPI negative cell populations. FlowJo Version 10.4.2 was used 
for the analysis. The same workflow, with the exception of the fatty acid loading step, was 
used to assess the impact of TOFA treatment on the lipid droplet content of the experimental 
cell lines. 
 
2.10 Fatty Acid Oxidation Assay 
MDA-MB-231, MCF7, T47D and BT474 cell lines were seeded into 96-well plate wells 
(CostarTM) at 7x104 cells per well and treated with either the vehicle, or 10 uM TOFA in 
DMSO. After approximately twenty hours the cells were assessed using a Fatty Acid 
Oxidation Assay (Abcam, ab217602) used in conjunction with an Extracellular O2 
Consumption Assay (Abcam, ab197243). The protocols accompanying the assays were 
followed to assess the cell lines after TOFA treatment. Experimental measurements were 
made using a Wallac EnvisionTM 2104 Multilabel Reader (Perkin-Elmer), maintained at 
37˚C throughout the course of the experiment. Excitation filter, UV (TRF) 340 and Emission 
filter APC665 were used to assess the status of the oxygen sensing probe used for the assay. 
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A measurement of the oxygen sensing probe was made every ninety seconds for one and a 
half hours. 
 
2.11 Growth Curves for 5-(Tetradecyloxy)-2-furoic acid (TOFA) sensitivity 
BT474, T47D, MCF7 and MDA-MB-231 cell lines were seeded into five, 96-well plates 
(CostarTM) at 1.5x104, 1.5x104, 1x104 and 0.5x104 cells/well respectively. Three wells in 
each plate were seeded for each experimental condition. An additional set of three wells 
were filled with growth media alone to act as a plate blank. On the day of seeding, after the 
cells had adhered to the plate and begun to spread, a single plate was fixed. Fixation was 
done by removing the culture media and adding 100 ul of 4% paraformaldehyde solution, 
PFA (HIMEDIA), to each well for ten minutes. The PFA was then removed and 100 ul per 
well of Crystal Violet Solution (Merck KGaA) was added to each well. After twenty minutes 
all non-cell associated Crystal Violet was removed by washing the wells with water. The 
cells in the remaining four plates were treated with either: growth media, growth media 
containing 0.13% DMSO or growth media with 10 uM TOFA (Sigma-Aldrich) in DMSO. 
A subsequent plate was fixed and stained as described above every twenty-four hours for 
ninety-six hours. Once plates were completely dry, 100 ul of Acetic Acid Glacial (Carlo 
Erba) was added to each well and incubated for twenty minutes at room temperature. Then 
the log optical density of each experimental well was measured at a wavelength of 570nm 
using a Wallace Victor3TM Multilabel Reader (PerkinElmer Inc.). Reported OD values 
were generated by subtracting the average of the three experimental wells from the average 
of the three plate blank wells.   
 
2.12 Transmitted light and fluorescence microscopy  
Mammosphere images were acquired with EVOS FL imaging system (Thermo Fisher 
Scientific, Inc., Waltham, MA) transmitted light microscope. Fluorescent images were 
acquired  with laser-scanning confocal microscopes: Leica TCS SP5 laser confocal scanner 
mounted on a Leica DMI 6000B inverted microscope equipped with motorized stage and 
HCX PL APO 63X/1.4NA oil immersion objective (Leica Mikrosysteme Vertrieb GmbH, 
Wetzlar, Germany) and Leica TCS SP2 AOBS laser confocal scanner mounted on a Leica 
DM IRE2 inverted microscope equipped with HCX PL APO 63X/1.4NA oil immersion 
objective (Leica Mikrosysteme Vertrieb GmbH, Wetzlar, Germany). For the excitation of 
fluorochromes dyes, 405 nm, 488 nm, 561 nm and 633 nm laser lines were used on Leica 
TCS SP5 and Leica TCS SP2 AOBS. The following settings were maintained for fluorescent 
images acquisition: digital zoom 2.5 and 1024x1024 scan format. 
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2.13 Kaplan-Meier Plotter 
Kaplan-Meier plots were generated using the Kaplan-Meier plotter found at 
http://kmplot.com/analysis/index.php?p=background (183). With this online platform, using 
the Affymetrix ID 209122_at dataset, we assessed the prognostic values for PLIN2 mRNA 
expression for a cohort of 3951 breast cancer patients.   
 
2.14 Statistical Analysis  
All experiments were carried out at least 3 times unless otherwise indicated. Data were 
analyzed using GraphPad Prism version 8 statistical software. Experimental results are 
reported as Mean and Standard Deviation unless otherwise stated.  
 
2.15 Animal models and in vivo studies  
Mice experiments were performed in collaboration with Giorgio Scita group, in accordance 
with the national laws and institutional guidelines for animal care (directive 86/609/EEC). 
Animal work was started upon the approval of the Italian Istituto Superiore di Sanità (license 
number 614/16). The maintenance of the NOD/SCID mice was done under specific 
pathogen-free conditions in the research animal facility of the IFOM/IEO (Milan, Italy). Free 
access to food and water, a 12-hour light-dark cycle and constant temperature were provided 
for the animals. 3 weeks old NOD/SCID female mice were used for the in vivo studies. 
Briefly, total MDA-MB-231 cells pre-incubated overnight with 1 µg/ml BODIPY were 
sorted for BODIPY intensity and 1.5 million cells from each subpopulation (5% BODIPYlow, 
5% BODIPYhigh, 5% BODIPYave) were mixed with Matrigel and Trypan blue and then 
injected into the mammary gland of the mice. Electron caliper was used every three days to 
measure the tumor size and the volume was calculated by multiplying [large diameter x 
(small diameter)2 x 𝛑/6].  Animals were sacrificed when first clinical signs of illness became 
apparent and tumors were collected.  
 
2.16 SDS-PAGE and Western blot analysis 
Cells were collected in PBS and lysed in RIPA Lysis Buffer (150 mM NaCl, 50 mM Tris 
pH7.6, 1% NP-40, 0.5% Na-deoxycholate, 5 mM EDTA plus protease inhibitors) for one 
hour on ice. 30 ug of lysate were then subjected to SDS-PAGE on 4-12% precast gradient 
gels (Invitrogen). Gels were run in running buffer at constant voltage of 120 V. Proteins 
were then transferred on Nitrocellulose membrane (Amersham 0.45 mm, GE Healthcare) in 
1X transfer buffer 20% Methanol for 1.5 hours at 100V 4˚C. After the transfer, membranes 
were washed in water and stained with Ponceau solution to check the transfer quality. After 
three washes in 1X TBS-T 0.1% tween, membranes were blocked for 1 hour at room 
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temperature in 1X TBS-T 5% milk or 1X TBS-T 5% BSA according to the antibody 
datasheet. The incubation with the primary antibodies was performed by gently shaking the 
membranes at 4˚C overnight. The day after, membranes were washed three times for 10 
minutes in 1X TBS-T and incubated for 1 hour at room temp. with the secondary antibody. 
Finally, membranes were washed thrice in 1X TBS-T and developed using ECL kit 
(Amersham) and images were acquired using Chemidoc (Bio-Rad, Molecular Imager 
Chemidoc XRS+). The list of antibodies is shown in Table 1.    
 
2.17 Pyruvate kinase assay 
Pyruvate kinase assay was performed following a published protocol from Worthington 
Biochemical. Phosphoenolpyruvate (PEP), Lactate dehydrogenase (LDH) and NADH were 
purchased from Roche. ADP and Fructose 1,6-biphosphate (FBP) were purchased from 
Sigma-Aldrich. In order to assess pyruvate kinase activity, a mixture containing 1300 
units/ml of LDH, 45 mM ADP, 6.6 mM NADH, 45 mM PEP in a 0.05 M imidazole-HCl 
buffer pH 7.6 containing 0.12 M KCl and 0.062 M MgSO4 was added to a 96-well plate in 
the presence or absence of FBP. To assess the pyruvate activity lysates or the recombinant 
protein were added to the mixture and then the reaction rate was calculated as the 𝛥-delta 
absorbance (Abs) read at 340 nm (25˚C) for minute.     
 
2.18 Fatty acids pull-down assay     
Fatty acid pull-down-assay was performed according to a previously published protocol 
(184). Shortly, Aminohexyl-agarose beads (SIGMA, A6017) were coupled to acyl chains 
with different length. The carboxygroups of the FA were activated by adding to a solution 
of 46 µmol dissolved lipids in 1ml dimethylformamide (DMF), 92 µmol N,Ndiisopropyl-
ethylamine (DIEA) and 35 µmol O-(benzotriazol-1-yl)-tetramethyluronium 
tetrafluoroborate (TBTU). After stirring the solution for 6 hours at room temperature, 0.5 ml 
of ω-aminohexyl-agarose beads in DMF was added and the suspension stirred overnight at 
RT. The coupled beads were washed with 1 ml DMF and twice with 1 ml PBS. To test the 
completeness of amino acid coupling we performed a Kaiser-test (185) .Cells were then 
washed with PBS and cell pellets lysed in NP-40 lysis buffer (150 mM NaCl, 50 mM Tris-
HCl pH 8, NP-40 1%, 2 mM DTT) containing protease inhibitors cocktail (Sigma-Aldrich 
for 30 minutes on ice. 50 µl lipid-beads were incubated with 50 ug pre-cleared lysate for 2 
hours 30 minutes on a rotating wheel. Beads were washed 4 times with 1 ml cold lysis buffer. 
Samples were separated by SDS-PAGE, stained with Coomassie Brilliant Blue or transferred 
to PVDF membranes for immunoblotting. 
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2.19 In vitro binding assay 
For the in vitro binding assay a chemically synthesized lipid probe prop-2-yn-1-yl-2-(3-
tridecyl-3-diazirin-3-yl) acetate was used to study the protein-lipid interaction. Briefly, 
proteins were incubated with or without the lipid probe for 1 hour at 25 ̊ C in dark conditions 
and then subjected to UV light at 345 nm for 10 minutes. Samples were then incubated with 
Alexa Fluor Picolyl Azide reagents (Molecular Probes, C10641) for Click-IT chemistry 
reaction for 1 hour at 25 ˚C for the detection and processed for SDS-page. Samples were 
visualized by Chemidoc fluorescent acquisition for Alexa Fluor 488 or stained with Instant 
blue (Expedeon).      
 
2.20 Production of recombinant Pyruvate Kinase M2 enzyme in Escherichia Coli 
2.20.1 Bacterial strains and preparation of competent bacteria cells 
Escherichia coli TOP10 and DH5alpha strains were used for the amplification and 
preparation of plasmid DNA. BL21 cells were used for the production of the recombinant 
proteins. BL21 and TOP10 competent cells were prepared with the calcium chloride 
procedure. Briefly, an overnight starting culture (10 ml) of E. coli in LB media was 
inoculated into 1 L of LB and grown until the optical density O.D. reached 0.4. Then, the 
cells were put on ice for 30’ and harvested by centrifugation at 3000g for 15’ at 4˚C 
(Beckman Coulter Avanti J-20 XP, rotor JA-10). The cell pellet was then resuspended into 
100 ml of ice-cold sterile MgCl2 and harvested again by centrifugation at 2000g for 15’ at 
4˚C. Pellet was now resuspended in 200 ml ice-cold CaCl2, incubated on ice for 20’ and 
harvested again as described above. The pellet was resuspended in 50 ml ice-cold 85 mM 
CaCl2 15% glycerol and centrifuged at 1000g for 15’ at 4˚C. Finally, 2 ml of ice-cold 85mM 
CaCl2 15% glycerol were used to resuspend the cell pellet that was then stored at -80˚C in 
50 ul aliquots.  
 
2.20.2 Generation of Pyruvate kinase M2 mutants through site-directed mutagenesis  
In order to generate PKM2_K422E, PKM2_K422R and PKM2_R489L mutants, site-
directed mutagenesis was performed using the Q5 High Fidelity DNA pol kit (BioLabs, 
M0491). Briefly,10 µl of 5X reaction buffer were mixed with 100 ng of pET-28a-hPKM2 
plasmid (Addgene – Plasmid #44242) DNA template, 2.5 µl of 10 µM oligonucleotide 
primer forward, 2.5 µl of 10 µM oligonucleotide primer reverse, 1 µl of 10mM dNTP mix, 
10 µl of 5X Enhancer solution and milli-Q H2O (primers list is shown in Table 3). Finally, 
0.5 µl of Q5 DNA polymerase was added before to start the PCR. After checking the DNA 
quality on a 1% agarose gel, the PCR product was subjected to DpnI digestion for 2 hours 
at 37˚C in order to remove the parental wild type plasmid.       
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2.20.3 Bacterial transformation 
TOP 10 bacterial competent E. coli cells were transformed with 15 µl of the PCR product 
after digestion. Briefly, 50 µl of TOP-10 cells were thawed on ice prior to the addition of 
PCR product. Cells were incubated with DNA on ice for 20’ and then subjected to heat shock 
for 45’’ at 42˚C. After the heat shock, cells were incubated again on ice for 2’. 1 ml of SOC 
medium was then added to the reaction tube and cell suspension was incubated on a shaker 
at 37˚C for 1 hour before plating onto LB-kanamycin (50µg/ml) plates. Finally, plated 
bacterial cells were incubated overnight at 37˚C. Colonies were picked from the plates grown 
for minipreps in 5 ml LB medium containing kanamycin in shaking incubator at 37˚C 
overnight.  Isolation of plasmid DNA was performed using Wizard Plus SV Minipreps DNA 
purification system kit (Promega, A1460). All the constructs were then validated by 
sequencing using the specific primers listed in Table 3.   
In order to express PKM2 wild type and PKM2_K422E mutant, 50 µl of BL-21 bacterial 
competent E. coli cells were thawed on ice prior to the addition of pET-28a-hPKM2 plasmid 
DNA (Addgene – Plasmid #44242) or pET-28a-hPKM2_K422E plasmid. Cells were 
subjected to the same procedure described above and plated onto LB-kanamycin (50µg/ml)-
chloramphenicol (50µg/ml) plates. Finally, plated bacterial cells were incubated overnight 
at 37˚C.    
 
2.20.4 Production of recombinant PKM2 wild type and mutants 
Single colonies were picked up from the LB-Kanamycin-Chloramphenicol plates and grown 
overnight into 40 ml Terrific Broth media (TB - tryptone, yeast extract, glycerol and 
potassium phosphate buffer) supplemented with 50µg/ml Kanamycin and 50µg/ml 
Chloramphenicol at 37˚C. Overnight culture was then diluted into 4 liters culture and grown 
until the optical density (O.D.) reached 0.9-1. Cells were then induced overnight at 18 ˚C 
with 0.5 mM IPTG at 225 rpm. The day after, the cultures were centrifuged and the pellet 
resuspended in Lysis buffer (10 mM HEPES pH 7.5, 300 mM KCl, 0.5% CHAPS, 12.5 mM 
imidazole, 5 mM MgCl2, 5% glycerol, 2.5 mM TCEP, in H2O) and sonicated for 2 rounds 
of 9 minutes each, 1 sec on- 1 sec off.  The sonicated cell solution was then centrifuged at 
19’000 rpm for 30 minutes 4˚C (Beckman Coulter Avanti J-20 XP, rotor JA 25-50). The 
supernatant was immediately removed, filtered using 0.22 µm filter unit (Thermo Scientific 
Nalgene, 595-4520) and incubated with 400 µl/liter culture His-Select Nickel Affinity Gel 
(SIGMA, P6611) for 90 minutes on a rotatic wheel. Beads were then washed for 10’ in lysis 
buffer and then the protein was eluted in elution buffer (10 mM HEPES pH 7.5, 300 mM 
KCl, 0.5% CHAPS, 200 mM imidazole, 5 mM MgCl2, 5% glycerol, 2.5 mM TCEP, in H2O) 
using 10 ml Poly-Prep Chromatography Columns Bio-Rad (7311550).  
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2.21 Analytical Size Exclusion Chromatography (SEC) 
For analytical SEC analyses 20 µM of PKM2_wt and PKM2_K422E mutant were loaded 
singularly on a Superdex 200 Increase 10/300 (GE Healthcare) equilibrated in 10 mM Hepes 
pH 7.5, 100mM KCl, 5 mM MgCl2, 5% glycerol, 1 mM DTT, and eluted in 0.5 ml fractions. 
The presence of the proteins in the elution volume was monitored by absorbance at 280 nm 
(expressed as mAu), and subsequently checked by SDS-PAGE followed by Coomassie 
staining. 
 
2.22 Static Light Scattering 
Static Light Scattering (SLS) analyses of PKM2 wild type and PKM2_K422E mutant were 
performed on a Viscotek GPCmax/TDA (Malvern, UK) instrument. The system was 
equilibrated in a buffer containing 10 mM Hepes pH 7.5, 100mM KCl, 5 mM MgCl2, 5% 
glycerol, 1 mM DTT and calibrated with BSA. PKM2 wild type and K422E mutants were 
loaded on the Viscotek GPCmax instrument equilibrated in a buffer containing 10 mM 
Hepes pH 7.5, 100mM KCl, 5 mM MgCl2, 5% glycerol and 1 mM DTT. About 150 µl of 
the samples concentrated at about 3 mg/mL were loaded on the columns, and eluted.  
 
2.23 Protein crystallization and structure determination 
2.23.1 PKM2_WT and PKM2_K422E sample preparation and crystallization conditions 
PKM2_wt and PKM2_K422E purified proteins were dialyzed overnight at 4 °C in 2 L 10 
mM HEPES pH 7.5, 300 mM KCl, 5 mM MgCl2, 5% glycerol, 2.5 mM TCEP buffer using 
Slide-A-Lyzer Dialysis Cassette G2 (Thermo Scientific, 87723) and then concentrated at 
about 5 mg/ml using Vivaspin 2 membrane 5,000 MWCO PES (Sartorius, VS0211).  
The proteins were subsequentially purified on a Hi-Load 16/60 Superdex 200 in 10 mM 
Hepes pH 7.5, 100mM KCl, 5 mM MgCl2, 5% glycerol, 1 mM DTT. Eluted fractions were 
then collected and concentrated to a concentration of 9 mg/ml for PKM2_WT and 5 mg/ml 
for PKM2_K422E mutant. Initial crystallization trials of the PKM2_WT were performed 
with the commercial screen Peg/Ion (Hampton Research) using 10 mM Hepes pH 7,5, 100 
mM KCl, 5 mM MgCl2, 5% Glycerol and 1 mM DTT buffer. 100 nl protein solution were 
mixed with an equal volume of reservoir solution at 20 °C. Crystals appeared after 2 days in 
about 30% of conditions containing PEG. Initial crystallization trials of the PKM2_K422E 
samples were set up with the commercial screens Peg/Ion (Hampton Research) and JCSG-
plus (Molecular Dimension) using a Mosquito nano-dispenser (TTP Labtech) in MRC 2 well 
crystallization plates (Swissci, Hampton Research), conducted in sitting-drop vapor-
diffusion. Again, 100 nl protein solution were mixed with an equal volume of reservoir 
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solution at 20 °C. Crystals appeared after 3 days in about 30 % of conditions containing 
PEG. 
 
2.23.2 Data collection, processing, and structure determination of PKM2_WT 
The best crystals of PKM2_WT grew in 0.1 M Hepes pH 7.5, 10% PEG 8000, 8% ethylene 
glycol and diffracted at 2.87 Å, belonging to space group P21. Crystals were analysed by X-
ray diffraction using the beamline PXIII of the Swiss Light Source (SLS), Villigen, 
Switzerland. Data processing, structure resolution and refinement were carried out by our 
collaborators of the Biochemistry and Structural Biology Unit of the European Institute of 
Oncology. The structure was solved by molecular replacement with Phaser (186), using 
chain A of pdb entry 6b6u as search model, with 4 molecules per asymmetric unit. The 
model was progressively optimized by iterative cycles of manual building in Coot (187), and 
refinement in Phenix (186). 
 
2.23.3 Data collection, processing, and structure determination of PKM2_K422E 
PKM2_K422E was purified, dialysed, concentrated to 5 mg/ml and subsequentially purified 
on a HiLoad 16/60 Superdex 200 as described above. Eluted fractions were then collected 
and used to set up crystallization trials with or without the addition of fatty acid. Diffracting 
crystals were obtained only with protein incubated with Oleic acid (Sigma Aldrich, 01383) 
in a 1:10 molar ratio overnight at 18°C. The complex was concentrated to 5 mg/ml. Initial 
crystallization trials were performed with the commercial screen JCSG+ (Molecular 
Dimension), Peg/Ion (Hampton Research) and Hampton 1-2 (Hampton Research) using 10 
mM Hepes pH 7,5, 100 mM KCl, 5 mM MgCl2, 5% Glycerol and 1 mM DTT buffer. 100 nl 
complex solution were mixed with an equal volume of reservoir solution at 20 °C. Crystals 
appeared after 7 days, but shapes and morphology required optimization. In order to obtain 
larger crystals and to slow down their growth, we performed a series of grid screens around 
the initial condition. Diffracting crystals grew in two different conditions. The first one grew 
in the presence of 18% PEG-3350, 275 mM di-ammonium tartrate, 17% proline and 0.8 mM 
oleic acid. The second one, instead, in 21% PEG-3350, 275 mM di-ammonium tartrate, 12% 
glycine and 0.8 mM oleic acid. Crystals were analysed by X-ray diffraction using the 
beamline PXIII of the Swiss Light Source (SLS), Villigen, Switzerland. They belong to the 
space group P1 and P21, with, respectively, 8 and 4 molecules in the asymmetric unit. 
Structures were solved by molecular replacement with Phaser (186), using chain A of pdb 
entry 6b6u as search model. The models were then progressively optimized by iterative 














Table 3. List of oligos 
 


















PKM2_K422E gtgaggcagaggctgc cgtcctcagcccagg Sequencing 
PKM2_K422R gtgaggcagaggctgc cgtcctcagcccagg Sequencing 
PKM2_R489L gtgaggcagaggctgc cgtcctcagcccagg Sequencing 
 
Protein Primary antibody Company Application 
PKM2 Anti-human PKM2 (D78A4) Cell Signaling WB 
TUBULIN Anti-human TUBULIN (T5168) Sigma Aldrich WB 
Secondary rabbit Anti-rabbit In house (IFOM) WB 
Secondary mouse Anti-mouse In house (IFOM) WB 
CD44 Anti-human CD44 VioBlue (130-
112-899) 
Miltenyi Biotec. FACS 
CD24 Anti-human CD24 Alexa Fluor 
647 (561644) 
BD Pharmingen FACS 
Oligo Sequence/Assay ID Application 
Sox2 Hs01053049_s1 RT-qPCR 
Pou5f1 Hs00742896_s1 RT-qPCR 
Klf4 Hs00358836_m1 RT-qPCR 
Aldh1a1 Hs00946916_m1 RT-qPCR 
Aldh1a3 Hs00167476_m RT-qPCR 
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Results I: Lipid droplets as a new marker of breast cancer stem cells 
 
All the results discussed in this chapter are published in the Journal of Clinical Medicine 
(JCM). The title of the article in which I contributed as co-first author is: “Lipid droplets 
define a sub-population of breast cancer stem cells” (Hershey B., Vazzana R., et al. 2019) 
(188).     
 
3.1 The correlation between lipid droplets content, breast cancer disease and stemness 
In order to investigate whether lipid droplets accumulation could impact on breast cancer 
disease progression, I tested whether in a cohort of 3951 breast cancer patients there was any 
correlation between the expression Perilipin2 (PLIN2) at the mRNA level (Affymetrix ID 
209122_at) and relapse free survival (R.F.S.). PLIN2, also known as adipophilin, is a well 
characterized lipid droplet structural protein, known to be important for LD biogenesis and 
is considered a LD specific marker. Using the Kaplan-Meier plotter, I estimated the 
probability of relapse free survival (183). As shown in the Kaplan Meyer survival curve in 
Figure 3.1a, the R.F.S. is significantly lower in patients with high PLIN2 expression 
compared to PLIN2 low expressing patients. Moreover, in the stratified analysis based on 
the four breast cancer subtypes, I observed that the significant negative correlation between 
PLIN2 expression and the survival rate is retained in all the subtypes, with the only exception 
of the HER2+ patients in which I could not observe any statistically significant difference 
(Figure 3.1b).  
 
Figure 3.1. Lipid droplets content as a marker of cancer progression. a Kaplan-Meyer survival 
curve showing relapse free survival (R.F.S.) in breast cancer patients with low (black curve) and high 
(red curve) PLIN2 expression. ****P value = 1.3e-14. b Kaplan-Meyer survival curve stratifying the 
patients based on the breast cancer type. P values: Basal ***p=0.00061; Her2+ p=0.49; Luminal A 

















































1976 1396 635 136 15 1low     
1975 1123 440 105 12 2high
HR = 1.54 (1.38 − 1.71)




































309 172 67 14 2low     
309 121 46 11 1high
HR = 1.55 (1.21 − 2.01)













































966 750 371 77 12 1low     
967 653 267 65 7 1high
HR = 1.46 (1.23 − 1.73)













5 1 1 2 0 25
Time (months)
























126 54 22 8 2low     
125 56 21 7 0high
HR = 0.87 (0.6 − 1.28)



















5 1 0 1 0
Time (months)
























575 387 153 34 1 0low     
574 326 128 25 2 1high
HR = 1.44 (1.19 − 1.75)



















0 50 100 150 200 2 0
Time (months)
 49 
I next sought to investigate whether the different breast cancer subtypes could be 
characterized by their lipid droplet content. With the attempt to have a panel of cells 
representing the most common breast cancer subtypes, I selected four different cell lines: 
BT474, belonging to the luminal B subtype (ER+, PR+, HER2+), MCF7 and T47D luminal 
A cells (ER+, PR+, HER2-), and MDA-MB-231 representing the triple negative (ER-, PR-, 
HER2-) breast cancer cell line (Table 4).    
 







Table 4. Classification of breast cancer cell lines based on receptors expression (183, 188-190). 
 
 
In order to visualize the intracellular lipid droplets, I took advantage of the lipophilic dye 
Nile red 5H-Benzo[α]phenoxazin-5-one,9-(diethylamino). Nile Red allows for 
discrimination between neutral lipids, like triacylglycerols and sterol esters that form the 
lipid droplets’ neutral core, that can be imaged using an excitation wavelength of 488 nm 
and an emission wavelength of 528, and charged lipids, like phospholipids included in all 
the organelle membranes whose excitation wavelength is between 515-560 nm and the 
emission > 590 nm (191). In line with this, I observed a robust lipid droplet staining in all 
four cell lines queried Figure 3.2a. The confocal images suggested that the lipid droplets 
content differed among the different cell lines. Therefore, using an ImageJ plug-in, I 
quantified the number of lipid droplets per cell for each cell line.  This analysis revealed that 
in comparison to the other cell lines, BT474 and MDA-MB-231 were significantly enriched 










Figure 3.2. Lipid droplets content heterogeneity in cells. a Representative images of Nile red 
stainings in BT474, MCF7, T47D and MDA-MB231 cell lines. Nuclei were stained with Dapi (in 
blue). Images were acquired using the Sp5 inverted confocal microscope, 63x oil immersion 
objective, 2.5x magnification. Scale bar 50 µm. b Quantification of lipid droplets number for cell 
considering 100 cells for each cell line. Data are represented as mean ± standard error of the mean 
(SEM). P value: ***p < 0.001, ****p < 0.0001. 
 
 
Intrigued by the observations about the accumulation of lipid droplets in the therapy resistant 
population of breast cancer patients (179), and the  hypothesis by which the metastatic 
disease can be generated from the subpopulation of cancer stem cells that survive the 
therapeutic treatment (177), I wanted to investigate whether there was any correlation 
between the accumulation of these organelles and stemness traits. To do so, I started my 
study analysing the gene expression profile of different cancer stem cells markers. 
Particularly, I evaluated the expression of five genes: sex determining region Y-box 2 
(Sox2), octamer binding transcription factor 4 (Oct4, also known as Pou5f1), Kruppel-like 
factor 4 (Klf4) and aldehyde dehydrogenase 1 family member 1 and 3 (Aldh1a1, Aldh1a3). 
Quantitative RT-qPCR data did not show consistent differences regarding the expression of 
these markers in our breast cancer cell lines panel, despite the increased expression of Sox2 
in BT474 and MDA-MB-231 cells (Figure 3.3).  
According to the cancer stem cell theory, tumours arise from a small population of cells 
capable to propagate, differentiate and with self-renewal properties. Due to the similarity 
with normal stem cells, we usually refer to them as Cancer Stem Cells (CSC). Recently, an 
in vitro approach was developed to isolate and characterize these cells in breast cancer. This 
system allows identification of CSCs based on their capability to survive and to form 
spheroids, in breast cancer called mammospheres, in non-adherent conditions (192). Further 
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differentiate to several lineages and characterized by the expression of CD44high/CD24low, a 
marker of breast cancer stem cells (193).  
 
Figure 3.3. Relative mRNA levels normalized to T47D cell line and obtained from quantitative PCR 
analysis of a panel of five stemness related genes. 
 
 
I decided to take advantage of this assay to test whether the four different cell lines harboured 
different capacities to form mammospheres. As shown in Figure 3.4a, I observed that all 
the cells were able to form mammospheres with varying efficiencies. Quantification of 
mammospheres formation efficiency, revealed a statistically significant difference between 
the cell lines (Figure 3.4b) that correlated with the previously quantified lipid droplet 
content Figure 3.2b. 
 
 
Figure 3.4. Lipid droplets accumulation correlates with stemness. a MDA-MB-231 
Mammospheres from BT474, MCF7, T47D and MDA-MB-231 cells. Images were acquired using 
EVOS fluorescence microscope. Scale bar represents 200 µm. b Mammospheres formation 
efficiency for the four cell lines used in this study. Significance was calculated using two tailed t-




































































Since the lipid droplets enriched cells were also the ones more efficient in the 
mammospheres formation, I decided to use BT474 and MDA-MB-231 cells to test whether 
I could observe lipid droplets enriched cells inside the mammospheres. To do so, I generated 
second generation mammospheres, I fixed them and stained using Nile red, as previously 
described. Remarkably, within all the grew secondary generation mammospheres, there was 
one or maximum two cells highly enriched in lipid droplets, suggesting a correlation between 
LDs and stemness properties (Figure 3.5).                
 
Figure 3.5. Second generation breast cancer mammospheres show lipid droplets enriched sub-
population of cells. Representative images of BT474 and MDA-MB-231 mammospheres stained 
with Nile red. Nuclei were stained with Dapi (in blue). The white arrows call attention to the lipid 
droplets highly enriched cells. Images were acquired using the Sp5 inverted confocal microscope, 
63x oil immersion objective. Scale bar 50 µm. 
 
 
Despite not having registered significant differences for the expression level of some stem 
cell markers in the global population, I observed interesting differences between the cell 
lines in mammosphere formation capacity. Moreover, the confocal images of the second 
generation mammospheres revealed a marked lipid droplet accumulation localized only in 
few cells. Taken together these data suggest a potential role of these lipid droplets enriched 
cells as progenitors with stemness traits.     
 
3.2 Cellular complexity is increased in lipid droplets enriched cells 
The Nile red staining suggested an important heterogeneity in lipid droplet content between 
the cell lines. Along the same line, I also realized that the lipid droplets content was not 
homogeneously distributed inside the same cell line, with some cells highly enriched in lipid 
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In an attempt to better understand whether the more enriched cells were harbouring stemness 
traits, I developed a method to isolate the lipid dropletshigh and lipid dropletslow 
subpopulations. To do so, I took advantage of a live cell marker of lipid droplets, BODIPYTM 
500/510 (Bodipy) that would permit us to isolate and collect the cells according to their lipid 
droplet content using a fluorescence activated cell sorting (FACS) based approach.  
I first tested the internalization of the Bodipy, a fluorescent fatty acid analogue (194), by 
confocal microscopy. As shown in Figure 3.6a (upper panel), all the four cell lines were 
able to internalize Bodipy, and the accumulation was mainly observed at the level of the 
lipid droplet suggesting that when read in the green channel the amount of Bodipy 
internalized by all the other membranous compartments could be neglected. As an additional 
control, I treated cells with the exogenous fatty-acids palmitic acid (50 µM) and oleic acid 
(100 µM), prior to the addition of Bodipy. Palmitic and oleic acids represent the most 
abundant, saturated and unsaturated fatty acids in the human plasma, respectively. The 
amount of fatty acids that I used in my assays are in the range of the physiological levels 
quantified by metabolomic studies as reported in the Human Metabolome Database (195).   
Exogenous fatty acid uptake should enhance lipid droplet accumulation. Indeed, I observed 
an increase in the lipid droplets content, as shown in the lower panel of Figure 3.6a. Having 
established that Bodipy specifically stained lipid droplets, I was ready to use it in a FACS 
based protocol.  
As I had previously used imaging to characterize the four cell lines for lipid droplet 
abundance, I then set out to determine whether I could confirm these results using a FACS 
based approach. Performing a FACS analysis on control (non-loaded) cells and Bodipy-
loaded cells, I observed the expected shift of the fluorescein isothiocyanate (FITC)  
Bodipy-signal in all four cell lines (Figure 3.6b). As appreciated in the histograms, we 
confirmed the differences in baseline levels of lipid droplets between the cell lines. Again, 
in order to ensure that the florescent signal could be attributed to lipid droplets we treated 
the cells with palmitic and oleic acids prior to the addition of Bodipy. As expected, pre-
treatment with fatty acids resulted in a quantifiable shift in the mean florescence intensity 
(Figure 3.6b). Interestingly, in addition to the Bodipy specific signal, careful observation of 
the scatter plots revealed a shift in the Side Scatter (SSC) of the Bodipyhigh populations. This 
shift was even more pronounced in the fatty acid loaded cells, suggesting an increase in the 
cellular complexity in lipid droplets enriched cells.  Therefore, I decided to include this 
parameter in our analysis. Taken, together the combination of SSC and Bodipy provided me 





Figure 3.6. The fluorescent fatty acids analogue Bodipy as a tool to isolate lipid droplets 
enriched cells. a BODIPY 500/510 stainings of lipid droplets (in green) in BT474, MCF7, T47D 
and MDA-MB-231 cells. In the upper panel control cells and in the lower panel cells loaded with 50 
µM palmitic and 100 µM oleic fatty acids. In both the conditions, cells were incubated for 12 hours 
with Bodipy. Images were acquired using the Sp5 inverted confocal microscope, 63x oil immersion 
objective. Scale bar 50 µm. b Side scatter vs forward scatter for total counted events in the absence 
of Bodipy, presence of Bodipy and Bodipy plus fatty acids loaded cells. The last panel merged panel 





3.3 Isolated lipid dropletshigh cells are characterized by stemness markers and properties 
The identification of the cancer stem cell population inside the tumour mass is still a limiting 
factor for effective therapeutic approaches. In breast cancer, a combination of markers is 
generally used to better distinguish and isolate the heterogeneous stem cell population. 
Among these markers, breast CSC have been shown to be particularly enriched in CD44 
(Cluster of Differentiation) and depleted in CD24 surface markers, the subpopulation of cells 
characterized by this phenotype is usually referred to as CD44high/CD24low (196). In order to 
investigate whether there was a correlation between the CD44high/CD24low markers 
expression and the lipid droplet enrichment, I performed flow cytometry analysis taking 
advantage of the bodipy-FACS approach described above. I decided to apply this approach 
to the MDA-MB-231 and BT474 cell lines. The distribution of the bodipy signal 
corresponding to lipid droplets in the main population is represented by the grey curve in the 
histogram in Figure 3.7a.  
 
Figure 3.7. Stem cell marker CD44high/CD24low enriched cells show a higher lipid droplets 
content. a Flow cytometry analysis of CD44/CD24 cell surface markers in BT474 and MDA-MB-
231 cells. Antibodies used include an anti-CD44 antibody conjugated to VioBlue and an anti-CD24 
conjugated to Alexa Fluor 647. Left panels show representative dot plots of CD44-VioBlue versus 
CD24-AlexaFluor647 expression for BT474 and MDA-MB-231 cells. Cells which fell in the upper 
left quadrant we considered to express the CSC phenotype of interest (CD44high/CD24low). In the right 
panel, the histogram represents the Mean Fluorescence Intensity (MFI) for Bodipy in 
CD44high/CD24low cells (red) versus the total population (grey). b Flow cytometry scatter plots for 
side scatter (SSC) versus forward scatter (FSC) of BT474 and MDA-MB-231 cells show an increase 
in cellular complexity for CD44high/CD24low cells.      
 
 
Interestingly, in comparison to the population, the CD44high/CD24low population represented 
by the red curve in the histogram, had a higher lipid droplet content in both cell lines. 
Moreover, CD44high/CD24low cells were also characterized by increased cellular complexity, 
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as shown in the side scatter (SSC) versus forward scatter (FSC) plot (Figure 3.7b). These 
data suggest that CSCs are enriched in lipid droplets.  
In order to demonstrate with a more direct approach that lipid droplets enriched cells were 
characterized by stemness traits, I needed to isolate this population of cells from the total 
population. I decided to perform these experiments focusing our attention on BT474 cells, 
since they were showing a higher lipid droplets content together with a better 
mammospheres formation efficiency. Taking advantage of the BODIPY-FACS sorting 
previously described according to their bodipy intensity, I isolated the top and bottom 5% 
cells, and referred to them as lipid dropletshigh and lipid dropletslow, respectively (Figure 
3.8a). Moreover, I also collected a control group of cells, from the total population, called 
lipid dropletsave sub-population. To be sure that the sorting procedure was efficient, I further 
checked the lipid droplets content in the sorted populations by Nile red staining and confocal 
microscopy. The Nile red staining confirmed that the Bodipyhigh sub-population of cells was 
indeed highly enriched in lipid droplets compared to the counterpart Bodipylow sub-
population (Figure 3.8b).  
 
Figure 3.8. The BODIPY-FACS sorting as a strategy to isolate lipid droplets enriched cells. a 
Bodipy 500/510 FACS sorting analysis of BT474 cells. Left panels show representative dot plots of 
BODIPY-FITC versus forward scatter (FSC) plot and the gating strategy used to isolate the two 
different sub-populations, bodipyhigh and bodipylow cells. In the right panel, the histogram represents 
the Mean Fluorescence Intensity (MFI) for Bodipy in the sorted cells. b Representative confocal 
images of sorted cells stained with Nile red. Nuclei were stained with Dapi (in blue). Images were 
acquired using the Sp5 inverted confocal microscope, 63x oil immersion objective, 2.5x 
magnification. Scale bar 50 µm. 
 
 
I wanted now to use the sorted cells to verify whether it was possible to score differences in 
the stemness traits among the three different sub-populations of cells. To do so, I evaluated 
the expression of several genes previously described as cancer stem cell markers. 
Interestingly, as shown in Figure 3.9a, the Bodipyhigh/lipid dropletshigh sub-population of 
cells shows a higher expression of all the analysed stem genes if compared to the Bodipylow 
cells, suggesting that the lipid dropletshigh population could be enriched in cancer stem cells. 
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Moreover, I also tested the capability of the sorted populations to form mammospheres. 
Importantly, also in this case, I observed a statistically significant increase in the 
mammospheres formation efficiency in the Bodipyhigh population compared to the Bodipylow 
(Figure 3.9b). All together these results demonstrate that the Bodipy-FACS based approach 
can be used to isolate sub-populations of cells according to their lipid droplets content. 
Moreover, my data demonstrate that the lipid droplets enriched cells have cancer stem cell 
features.  
 
Figure 3.9. Lipid dropletshigh sub-population shows stemness traits. a RT-qPCR of the indicated 
genes, marker of stemness, in BT474 cells following the BODIPY-FACS sorting. The three groups 
represent the Lipid dropletsAve, Lipid dropletsLow and the Lipid dropletsHigh sub-populations. Data are 
shown as geometric mean ± standard deviation. b Mammospheres formation efficiency for the three 
different sub-populations of sorted cells. Significance was calculated using two tailed t-tests; P value: 
*p<0.05, **p<0.01, ***p<0.001. 
 
 
3.4 In vivo tumorigenic potential of Lipid dropletshigh cells  
In order to determine whether the observed stem traits were associated with in vivo 
tumorigenic potential, I decided to inject the BODIPY-FACS sorted sub-population of cells 
into the mammary glands of immuno-compromised mice (Figure 3.10a). These in vivo 
studies were performed in collaboration with Emanuela Frittoli, from the IFOM Mechanisms 
of tumour cell migration laboratory headed by Giorgio Scita.    
To do so, I firstly isolated the three different polulations of cells according to the lipid 
droplets content, LDhigh (or Bodipyhigh), LDlow and LDave cells; then I injected 300,0000 cells 
in each mammary gland and monitored tumor onset.  
Despite the observation that all three populations, LDave, LDhigh and LDlow,  were able to form 
tumours, LDhigh populations showed a more rapid onset compared to the LDlow or LDave 
populations (Figure 3.10b). These findings demonstrate that the lipid droplet enriched cells 
(LDhigh) show an higher tumorigenic potential. Taken together these results demonstrate the 
role of lipid droplets as a marker of cells harbouring increased tumorigenic potential both in 
vitro and in vivo.   
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Figure 3.10. In vivo tumorigenic features of Lipid dropletshigh cells. a Schematic representation 
of the strategy used for the in vivo studies. Triple negative MDA-MB-231 BODIPY-fluorescence 
activated sorted cells were injected into NOD/SCID mice. b Tumor Free Survival percentage for the 
in vivo studies of each group of mice injected with the Bodipy-sorted cells. 300.000 LDhigh or LDlow 
cells were injected for mammary gland. The three groups of mice included n=4 mice for LDlow, n=9 
mice for LDave and n=4 mice for LDhigh.  Significance was calculated using two tailed t-tests; P value: 
*p<0.05.    
 
3.5 Breast cancer cell lines dependencies from the de novo fatty synthesis  
These results suggesting increased cancer stem cell related traits in the lipid droplet enriched 
cells, led me to ask whether I could modulate the tumorigenic potential by interfering with 
lipid metabolism.  One of the main dysregulated lipid metabolic pathways in cancer cells is 
the de novo fatty acids (FA) synthesis pathway. Starting from acetyl CoA, malonyl-CoA is 
generated in a reaction catalyzed by Acetyl CoA Carboxylase alpha (ACC-alpha) enzyme 
(197) (Figure 3.11a).  
 
Figure 3.11. TOFA inhibits malonyl-CoA production and fatty acids beta oxidation. a Cartoon 
showing the effects of TOFA inhibitor on cellular lipid metabolism. b Fatty acid beta oxidation assay 
performed in the panel of breast cancer cell lines after 24 hours of 10 uM TOFA exposure. Each 
regression line represents the 95% confidence interval. Asterisks indicate statistical significance 
detected at the 0.001*** probability level. 
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This enzyme has a key role in the cellular micro-environment since malonyl-CoA generation 
is fundamental not only for fatty acids biosynthesis but also for the inhibition of carnitine 
palmitoyl-transferase enzyme which regulates the fatty acids beta oxidation pathway, 
catalyzing the transfer of acyl chains to carnitine with the consequent translocation of acyl-
carnitine from the cytoplasm to the mitochondria (198). In order to block the de novo fatty 
acids synthesis, I treated the breast cancer cell lines used in this study with the ACC-alpha 
chemical inhibitor TOFA (5-tetradecyloxy-2-furoic acid). TOFA acts as an allosteric 
inhibitor of ACC-alpha since, once internalized by the cells, is converted to TOFyl-CoA, 
thus competing with acetyl-CoA for the binding (199).   
Cells were evaluated for lipid droplet content at 48 hours post-treatment with 10 uM TOFA. 
Following treatment, I scored a reduction in the lipid droplet content of BT474, MCF7 and 
T47D cell lines in comparison to the control or the vehicle treated cells.  
The lipid droplet content was evaluated both with Nile red staining, as shown in Figure 
3.12a, and the previously described BODIPY-FACS (Figure 3.12b). Interestingly, the 
MDA-MB-231 cells, did not show a TOFA dependent drop in lipid droplets, suggesting that 
they may be more dependent on exogenous fatty acids, or conversely less dependent on 
mitochondrial Beta-oxidation as an energy source.   
In order to test if the reduction in malonyl-CoA production was affecting also other lipid 
metabolic pathways, I also evaluated the capability of the cells to oxidize fatty acids taking 
advantage of a commercial fatty acid oxidation (FAO) assays.  As shown in Figure 3.11b, 
with the exception of MDA-MB-231 cells, TOFA treated cells show a statistically 
significant reduction in fatty acids oxidation compared to the control cells, suggesting the 
existence of a futile cycle in these three cell lines. This could be due to the reduction of 
malonyl-CoA production that can lead to the inactivation of the carnitine-palmitoyl 
transferase enzyme.     
Interestingly, MDA-MB-231 cells seem to not be affected by the TOFA treatments. Indeed, 
the lipid droplets content did not show any decrease and also fatty acid oxidation levels were 
not affected by the inhibitory effect of TOFA. This could be due to an intrinsic resistance to 
the inhibitor, for example, based on mutations at the TOFA binding site of ACC-alpha, or to 
the up-regulation of alternative pathways able to sustain fatty acids production. Further 









Figure 3.12. De novo fatty acids synthesis inhibition blocks lipid droplets accumulation. a 
Representative images of Nile red stainings in BT474, MCF7, T47D and MDA-MB-231 control 
cells, vehicle and TOFA treated for 48 hours with vehicle (DMSO) or 10 uM TOFA. Nuclei were 
stained with Dapi (in blue). Images were acquired using the Sp5 inverted confocal microscope, 63x 
oil immersion objective. Scale bar 50 µm. b BODIPY-FACS analysis of the cells treated with vehicle 
or TOFA for 48 hours. The upper panel represents the Bodipy signal for all the conditions analyzed; 
the bottom panel shows the side scatter vs forward scatter plots for total counted events in control, 





Since I demonstrated that lipid droplets enriched cells show a cancer stem cells phenotype, 
I wanted to evaluate whether targeting the de novo fatty acids synthesis and thus the lipid 
droplets accumulation, I could score any difference in the tumorigenic capacity of the cells. 
To do so, I first wanted to evaluate the proliferation rates of the cells in the absence or 
presence of TOFA inhibitor. As shown in Figure 3.13a, with the exception of the MDA-
MB-231 cell line, cells treated with 10 µM TOFA had a significant reduction in the cellular 
growth compared to the control or the vehicle treated cells.  
 
Figure 3.13. TOFA inhibits the proliferation potential. a Cellular growth for the breast cancer 
cell panel in control cells versus vehicle or TOFA treated cells. Significance was calculated using 
the multiple unpaired t-test. P value: *p<0.05, **p<0.01, ***p < 0.001. b Second generation 
mammospheres formation assay performed in BT474 and MDA-MB-231 cells after 5 days of vehicle 
or TOFA treatments (n=2).  
 
 
Moreover, to assess whether the reduction of the LD content observed in the TOFA treated 
cells affected the cancer stem cells traits, I compared mammosphere formation between 
BT474 and MDA-MB-231 cells following an acute 5-day treatment with TOFA. 
Importantly, the assay was performed in free-TOFA media in order to avoid any possible 
effect on the cellular growth mediated by the presence of the inhibitor. In this way, I was 
able to observe the behaviour of cells that survived the TOFA treatment, with either (1) 
decreased LD content (as shown in Figure 3.12) (BT474) or (2) no effect (MDA-MB-231). 
Interestingly, I scored a reduction in the mammosphere formation efficiency in TOFA 
treated BT474 cells compared to the control cells (Figure 3.13b). Importantly, in line with 
their non-responsiveness to TOFA treatment, MDA-MB-231 cells did not show any 
difference in cellular proliferation rates or in the mammosphere formation capacity among 
the three groups (control, vehicle or TOFA). The observation that TOFA sensitive cells had 
reduced MFE strengthened the correlation between the LD content and the tumorigenic 
capacity.     











































































































































































































Results II: The biochemical interplay between glucose and lipid metabolism 
 
4.1 PKM2 activity is differently regulated in a panel of breast cancer cell lines 
Cellular metabolism includes all the biochemical reactions necessary to provide ATP based 
upon glucose, lipids or, in a lower fraction, proteins catabolism. According to the Randle 
cycle theory, also known as the “glucose-fatty acid cycle”, there is a competitive mechanism 
between the usage of the two main cellular fuels, fatty acids and glucose. Specifically, 
Randle focused on the competition between glycolysis and fatty acid oxidation (FAO), since 
he observed that the accumulation of one of the two metabolites, glucose or fatty acid, at the 
cellular level was able to inhibit the other pathway. It is now known that Malonyl-CoA, a 
basic building block in de novo fatty acid biosynthesis, inhibits CPT1, thus blocking entry 
of fatty acids into the mitochondria for consumption via beta-oxidation. In addition to the 
work done by Randle, in the late 1960s several studies demonstrated that long and short 
chain fatty acids were able to inhibit glycolytic enzymes hexokinase and pyruvate kinase, 
although the mechanism behind the fatty acid mediated inhibition remains unknown (72, 
200).   
Pyruvate kinase M2 (PKM2) enzyme plays a key role in the regulation of the glycolytic flux, 
since it catalyses the terminal reaction of glycolysis. The previously mentioned observations 
regarding a potential role for fatty acids in regulating PKM2 activity and the important role 
played by PKM2 in cancer, led me to investigate whether there was a direct interaction 
between fatty acids and PKM2. To do so, I started analysing the expression and activity of 
PKM2 in a panel of ten breast cancer cell lines. As shown in Figure 4.1a, the protein 
expression levels are very similar in all the cells that I tested. Taking advantage of a 
previously published protocol from Worthington Biochemical, I measured the pyruvate 
kinase activity in a lactate dehydrogenase coupled assay system (Figure 4.1b).  
 
Figure 4.1. Pyruvate kinase M2 expression and activity. a Immunoblot analysis of PKM2 
expression in a panel of ten breast cancer cell lines. b In vitro pyruvate kinase assay. The upper part 
shows the schematic representation of the in vitro assay used in our study. The lower panel shows 
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Measuring the decrease in the absorbance at 340 nm coming from the NADH oxidation, I 
analysed the PKM2 activity across the cell line panel and I interestingly found that, despite 
similar levels of total protein, PKM2 activity differed significantly between the cell lines.   
 
4.2 Specific interactions between PKM2 and fatty acids 
Thus, I selected BT474 cell line, which showed the highest PKM2 glycolytic activity, and I 
assessed the PKM2 capability to bind to fatty acids by performing a fatty acid pull-down 
assay. Following a previously published protocol (184), I first conjugated the aminohexyl-
agarose beads with fatty acids of various chain lengths (Figure 4.2a). Then, after evaluating 
the efficiency of the conjugation of the fatty acids to the agarose beads using the Kaiser test 
assay (185), I used whole cell protein extracts from exponentially growing BT474 cells to 
perform pull-down assay followed by immunoblotting analysis. As shown in Figure 4.2b 
(left upper-panel), using the cellular lysates, I observed a strong interaction between PKM2 
and all the fatty-acids tested. Conversely, PKM2 did not interact with the unconjugated 
control beads, suggesting that PKM2 can bind to lipids. 
 
Figure 4.2. PKM2 binds fatty acids. a Schematic representation of the four different fatty-acyl 
beads used in this assay. The preparation of fatty-acyl co-Aminohexyl-agarose beads was performed 
as described by E. Beck-Garcia et al. 2013. b Western blot analysis for PKM2 after the fatty acid 
pull-down assay for BT474 cells (left panel - upper part), recombinant PKM2 protein (left panel - 
lower part) and Western blot analysis for Hexokinase, Phosphofructokinase and PKM2 post-pull 
down (right panel). c Western blot analysis for PKM2 after the fatty acid pull-down assay using 
recombinant PKM1 and PKM2 proteins. 
        
 
I then expanded the analysis using the other two glycolytic enzymes considered glycolytic 
gatekeepers, since they catalyse the other two unidirectional reactions of glycolysis, 
Hexokinase 1 (HK1) and Phosphofructokinase P (PFKP). The in vitro pull-down assay 













































































































































































































































panel), suggesting a potential direct mechanism based on physical interaction behind the old 
observations made by Lea and collaborators concerning fatty-acids mediated hexokinase 
inhibition (200). PFKP was, instead, a-specifically binding in all conditions including the 
unconjugated control beads. In order to assess if the observed binding was due to a direct 
interaction or was modulated by co-factors, I decided to assess the lipid binding property of 
the recombinant PKM2 protein produced in Escherichia coli. Interestingly, the binding with 
the fatty acids was maintained, albeit reduced, by the recombinant PKM2 protein, 
confirming a direct interaction between the enzyme and the tested fatty acids (Figure 4.2b, 
lower panel).  
PKM2 protein sequence arises from the same transcript that also generates Pyruvate Kinase 
M1 (PKM1) protein, through an alternative splicing event. The two proteins differ for the 
presence of exon 9 in PKM1 and exon 10 in PKM2. This important difference confers upon 
PKM2 the ability to tune its activity through allosteric regulation, while PKM1 is 
constitutively active (201). In order to test whether PKM1 was also able to bind lipids, I 
purified the recombinant protein and again performed the fatty acid pull-down assay using 
oleic acid and the two (PKM1 and PKM2) recombinant proteins. Interestingly, PKM1 did 
not appear to bind the oleic acid, while the interaction was confirmed for PKM2 (Figure 
4.2c). I observed that, although the rPKM2 was able to bind to lipids, the binding was 
reduced in respect to that seen from lysates. This observation led me to ask why that might 
be. Focusing specifically on the potential lipid binding capacity, I used a published tool (202) 
to analyze the amino acids properties of PKM2 and to create a hydrophobicity plot. The 
analysis revealed that PKM2 harbors a specific region particularly enriched in hydrophobic 
residues (Figure 4.3), suggesting a potential region of interaction of the protein with 
hydrophobic molecules like lipids. This region lies within the inter-subunit contact region, 
within close proximity to the FBP binding site, suggesting that availability of PKM2 to bind 
to fatty acids may depend on its multimerization state.   
From a structural point of view, the main difference between the two isozymes is that while 
PKM1 is a stable tetramer, PKM2 alternates two different conformations, switching from a 





Figure 4.3. PKM2 sequence shows highly enriched hydrophobic regions. Hydropathy plot of 
PKM2 amino acids sequence. Sequences in the upper part are hydrophobic (>0), while sequences in 
the lower part are hydrophilic (<0). The hydrophobic peak at the 426 residue represents the highest 
hydrophobic region and belongs to PKM2 inter-subunit contact domain region. The hydropathy plot 
is based on the Kyte and Dolittle algorithm and was created using the EMBL-EBI sequence analysis 
tool APIs.  
 
 
Therefore, I hypothesized that a possible interaction site could be exposed in the dimeric 
form of PKM2. This idea, reinforced by the hydropathy plot data, is further supported by 
analysis of the crystal structure from which one can appreciate the cluster of highly 
hydrophobic regions, showed in dark blue in Figure 4.4 (RCSB Protein Data Bank: 3U2Z), 
positioned within the dimer:dimer interface.  
 
Figure 4.4. Crystal structure of PKM2 wildtype tetramer. Each monomer is displayed in a 
different color. In white, light purple, light yellow and salmon respectively chains A, B, C and D. 
Dimer 1 is formed by chains A and B, Dimer 2 by chains C and D. In dark blue are represented the 


























         












4.3 Generation of recombinant PKM2 mutants in E. coli  
Since the hydrophobic region is mostly present at the PKM2 dimer:dimer interface, I 
hypothesized that this region could regulate the stabilization of the dimeric or tetrameric 
form of PKM2. Therefore, based upon literature and structure-function analysis, I selected 
residues, that once mutated, might affect the quaternary structure of the protein. In particular, 
I focused on lysine 422 (K422) as its mutation to arginine has been previously shown to 
modulate the activity and to promote conformational changes on PKM2 structure (203). 
Indeed, it is a critical residue as it is located within the previously identified hydrophobic 
patch in the inter-subunit contact domain (Figure 4.5b). The second residue I selected was 
the arginine 489 (R489). The mutation of this arginine to leucine has been shown to abrogate 
the FBP binding capacity (204), thus altering the FBP mediated-allosteric regulation.  
Conducting site directed mutagenesis of the parental WT_PKM2 coding sequence, I 
generated the PKM2_R489L mutant and two different PKM2_K442 mutants: 
PKM2_K422R and PKM2_K422E. As described before, the first one is characterized by the 
same mutation reported in patients K422R and, the second one, K422E, where the lateral 
amino acid chain of the glutamic acid imparts a negative charge to the patch. 
 
Figure 4.5. Size exclusion chromatography (SEC) analysis of PKM2 mutants. a Proteins were 
separated and analyzed using Superdex 200 Increase analytical SEC column. The chromatogram 
displays the UV at 280 nm curve for the three PKM2 mutants. The elution profile of globular markers 
is reported as dashed grey lines. b PKM2 crystal structure. The yellow lines represent the Lysine 422 




Recombinant proteins have been expressed and purified in E. coli. Then, with the help of the 
Biochemistry and Structural Biology Unit of the European Institute of Oncology, we have 
analyzed their oligomeric state by analytical Size Exclusion Chromatography (SEC). As 
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shown in Figure 4.5a, SEC runs suggested that both the PKM2_K422R and PKM2_R489L 
assemble as tetramers (yellow and red curves respectively). On the other hand, 
PKM2_K422E was mainly present in a dimeric form, as shown by the blue curve in Figure 
4.5a. Having assessed that among these mutants, the only one that purified as a stable dimer 
was PKM2_K422E, I choose this mutant to better characterize the putative PKM2:fatty acid 
interaction. 
 
4.4 Biochemical characterization of PKM2_K422E mutant 
 In order to determine the oligomerization state of PKM2_Wild type and the K422E mutant 
and to check their homogeneity, we first ran an analytical gel filtration by loading the two 
proteins on a Superdex 200 Increase column. As shown in Figure 4.6a, both the samples 
eluted as a single peak, with PKM2_WT eluting slightly before the 158 kDa molecular 
weight marker and K422E mutant after the 158 kDa, suggesting that most likely they 
respectively elute as tetramer and dimer in solution. Yet, since SEC does not provide 
absolute values for molecular weight and elution profiles can be influenced by folding, in 
order to assess the absolute molecular weight, we performed a static light scattering analysis 
(SLS). This technique provides a measure of the specific molecular weight by recording the 
intensity of light scattered by the sample in solution. The SLS analysis confirmed that while 
PKM2_WT is a tetramer in solution, with a measured molecular weight of 236.4 kDa, 
PKM2_K422E is dimeric with a 121.5 kDa mass (Figure 4.6b). As shown in Figure 4.6c, 
the estimated molecular weights are very close to the theoretical predicted ones.  
It has been reported that tetramerization is required for PKM2 to act as the canonical 
glycolytic enzyme. Given that the PKM2_K422E mutant purified as a dimer, I did not expect 
it to be able to convert phosphoenolpyruvate to pyruvate. To test this, I performed the 
previously described pyruvate kinase activity assay. Comparing a range of PKM2_WT 
concentrations from 12,5 ng-50 ng/reaction to 50 ng of K422E mutant activity, I observed a 
significant reduction of pyruvate kinase activity in the mutant (Figure 4.6d). All together 
our SEC and SLS data demonstrated that PKM2_K422E mutant is expressed as a stable 




Figure 4.6. Characterization of PKM2_K422E mutant. a SEC elution profile of PKM2_WT and 
PKM2_K422E run on a Superdex 200 increase. The chromatogram shows the UV at 280 nm. 
Molecular weight markers are shown in grey. In the lower part Coomassie stained of the SDS-page 
of the peak fractions corresponding to the horizontal black bar. b Static light scattering (SLS) analysis 
of PKM2_WT and K422E mutant. In blue is shown the UV Absorbance trace (left Y axis) and the 
measured molecular weight in red (right Y axis). The analyses show an average molecular mass of 
236.4 kDa and 121.5 kDa along the peaks which are consistent with a tetramer for PKM2_WT and 
a dimer for PKM2_K422E. c Table showing the comparison between the theoretical molecular 
weights and the molecular weight measured by SLS. d Pyruvate kinase activity assay of PKM2_WT 




4.5 Dimeric PKM2 exhibits higher in vitro binding affinity to fatty acids 
Since I demonstrated that PKM2_K422E mutant is a stable dimeric form of the enzyme, I 
decided to use this mutant to verify whether the dimeric form of the enzyme is, indeed, more 
prone to bind lipids compared to the tetrameric form, as our data suggested.  
I reasoned that since I already observed a binding between PKM2_WT and palmitic acid in 
the fatty acid pull-down assay, also a chemical lipid probe C:16 should be able to bind the 
protein; then, thanks to the terminal alkyne group, C:16 can react with Alexa Fluor Picolyl 
Azide allowing me to detect the interaction. Hence, I set up an in vitro binding assay using 
the chemical lipid probe prop-2-yn-1-yl-2-(3-tridecyl-3-diazirin-3-yl) acetate. This lipid 
probe is an alkynyl-cis-palmitic acid (C 16:0) which contains a photoactivatable diazirine 
group and an alkyne handle and it represents a useful highly sensitive tool for studying lipid: 
protein interactions in in vivo and in vitro systems (Figure 4.7a). The alkyne group is able 
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to react with fluorescent azides through a copper-catalysed cycloaddition, known as “click 
chemistry” reaction allowing for visualization of probe binding both in vitro and in vivo 
(205). Using this tool, I compared the in vitro binding efficiency of the lipid probe with the 
WT tetrameric protein and the K422E dimeric mutant.  
Thus, I incubated both the proteins with or without the lipid probe for 1 hour at 25 ˚C and 
then all the samples were subjected to UV light at 345 nm to activate the diazirine group. 
Samples were then incubated with Alexa Fluor Picolyl Azide reagents (Molecular Probes, 
C10641) for detection and processed for SDS-page. The in vitro binding assay with the 
chemical lipid probe showed that both the tetrameric WT protein and the dimeric mutant 
were able to bind the lipid (Figure 4.7b). Strikingly, the dimeric K422E mutant showed a 
stronger affinity compared to the WT protein, suggesting that the highly hydrophobic region 
included into the dimer:dimer interface can represent the region with the highest affinity 
towards hydrophobic molecules.  
 
Figure 4.7. Fatty acids preferentially bind the dimeric form of PKM2. a Schematic 
representation of the in vitro binding assay used. A chemical synthesized lipid probe C19 H32N2O2 
(C16_LP) was used for a Click-IT chemistry reaction. PKM2_WT and K422E mutant were incubated 
with and without 30 uM C16_LP_N3 and 30 uM palmitic acid (1:3 ratio protein:lipids) and exposed 
to UV light at 345 nm. b Samples were subjected to SDS-page and visualized by a Chemidoc 
fluorescent acquisition for Alexa Fluor 488 (upper panel) or stained with Coomassie blue (lower 
panel). c Samples were subjected to the same procedure described before with and without UV light.     
 
 
In order to assess whether I could observe a competitive mechanism between the chemical 
lipid probe C:16 and the fatty acid palmitic acid (C 16:0), I performed the same assay also 
in the presence of equimolar concentration of palmitic acid. Interestingly, while for the 
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dimeric K422E mutant I did not observe any significant difference in the chemical probe 
binding capacity in the absence or presence of palmitic acid, unexpectedly, for the WT 
tetrameric protein I observed a slightly increase in the binding capacity to the chemical probe 
in the presence of the fatty acid (Figure 4.7b). This enhancement of binding was confirmed 
for fatty acids of shorter chain lengths as well. These data suggest that exposure to fatty acids 
could facilitate the binding of the WT protein to the chemical probe. Thus, necessitating the 
need for further structural studies of fatty acid:PKM2 complexes. 
Finally, as a technical internal control, I performed the in vitro binding assay with or without 
the UV light exposure, which leads to covalent attachment of the lipid probe to bound 
proteins through the diazirine group. As shown in Figure 4.7c, in the absence of UV light 
there is no binding between the tetrameric PKM2_WT protein and the chemical lipid probe 
(left panel), while a light band appears for the dimeric K422E mutant (right panel). This 
experiment confirms the specificity of the technique and shows that the dimer, even in the 
absence of the photo-activated diazirine group, displays a basal level of interaction with the 
chemical lipid probe.   
   
4.6 Crystal structure of PKM2_WT   
Understanding the properties and the function of the proteins and the interaction with other 
macromolecules is greatly facilitated by structural analysis. Thus, to better characterize the 
role of the Lys422 to Glu mutation at the structural level, and to map the residues 
coordinating the fatty acid binding to the PKM2_K422E mutant, in collaboration with the 
Biochemistry and Structural Biology Unit of the European Institute of Oncology (IEO), we 
initiated the structural investigation of the protein and its interaction with fatty acids.  
As a starting point for the structural analysis, we both tried recapitulating the previously 
published crystallization conditions for the bacterially produced PKM2_WT protein (40) 
and, in parallel, set up a general screening of crystallization conditions using the commercial 
screen Peg/Ion and JSCG+ from Hampton Research. Commercial crystallization kits are 
designed to allow sampling of crystallization space by making use of several different 
conditions, which vary in pH, salts and type of precipitant reagents. We set up crystallisation 
trays with different protein concentrations and ratios of protein:reservoir volume, eventually 
managing to obtain crystals in about 30% of the commercial screen conditions. For the wild 
type protein, it was not necessary to further optimize the conditions, since the crystals 
obtained with the commercial screen were already single and of an appropriate size for 





Figure 4.8. Crystals of PKM2_wild type. Crystals of PKM2 WT grown by sitting drop vapor 
diffusion using the commercial screen Peg/Ion. The first crystals appeared after two days of 
crystallization mixing the protein sample with 10 mM Hepes pH 7.5, 100 mM KCl, 5 mM MgCl2, 
5% glycerol and 1 mM DTT (left). Crystals grew in the presence of 0.1 M HEPES pH 7.5, 10% PEG 
8000, 8% ethylene glycol. On the right the diffraction of PKM2 WT crystals. 2.8 Å resolution X-ray 




Crystals grown in 0.1 M Hepes pH 7.5, 10% PEG 8000, 8% ethylene glycol were harvested 
and flash cooled in liquid nitrogen using a cryo-protectant solution containing 20% glycerol, 
to allow cryogenic X-ray diffraction data collection, which was performed at beamline 
X06DA (PXIII) of the Swiss Light Source synchrotron (Villigen, Switzerland). Crystals 
diffracted to 2.87 Å resolution, and belonged to P21 space group. The structure was solved 
by molecular replacement by our collaborators, and refinement is still ongoing. Table 5 
reports the data collection statistics and the current state of model refinement. 
Recent structural studies have described the existence of two different conformations for the 
tetrameric state of PKM2. The protein can assemble into an active state, named R-state, and 
a less active state, or T-state. Allosteric inhibitors, like phenylalanine, have been correlated 
with the stabilization of the less active T-state, while the allosteric activator FBP is involved 
in the stabilization of the active R-state (65). From a structural point of view, the T-state 
adopts a conformation in which a general rotation of 13˚ of all the four chains is observed in 
the comparison with the R-state. In my in vitro pyruvate kinase assays I have previously 
shown that the WT protein is active in glycolysis. In order to verify whether our PKM2_WT 
crystal structure adopted the active R-state conformation, we decided to align it with two 
different PKM2 crystal structures previously published as R-state structures. Alignment 
analyses were conducted with the help of Janine Weber, a postdoctoral fellow of the IFOM 
Molecular machines in signaling pathways laboratory headed by Simona Polo.  
The two different crystals that we used for this comparison are deposited on the RCSB 
Protein Data Bank as 4FXF (65) and 4RPP (206) and represent respectively PKM2_WT and 
PKM2_K422R mutant, both in complex with FBP. The alignments showed that our PKM2 
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WT structure perfectly recapitulates the deposited R-state crystal structures (Figure 4.9), 
confirming the active state of the protein.  
 
 
Figure 4.9. Structural comparison of PKM2 WT and PKM2 in R-state. Superimposed crystal 
structures of our PKM2 WT (magenta) with two previously published crystal structures of PKM2 
WT and PKM2_K422RFBP in the active R-state (light brown and orange). Alignments were created 
using the PyMOL software. The PDB code of the published PKM2 structures are 4FXF for the PKM2 
WT and 4RPP for the PKM2_K422R mutant. Their atomic coordinates are deposited on the RCSB 
Protein Data Bank.      
 
 
4.7 Crystal structure of PKM2_K422E mutant   
Having identified the best conditions for the crystallization of the wild type PKM2 protein, 
we moved forward with our goal of crystallizing the K422E mutant in combination with 
Oleic acid. Thus, identifying the fatty acid binding pocket required to bind fatty acids, as 
demonstrated by my in vitro experiments. I proceeded in parallel to set up the crystallization 
of PKM2_K422E alone and in combination with Oleic acid. PKM2_K422E was prepared 
following the previously described protocol of PKM2_WT. Instead, for PKM2_K422E in 
combination with fatty acids, I incubated the protein with Oleic acid in a 1:10 molar ratio 
overnight at 18˚C. Both PKM2_K422E and the pre-incubated protein with Oleic acid, were 
then concentrated to 5 mg/ml. Crystallization trials were performed using the Peg/Ion and 
JCSG-plus screens from Molecular Dimension Ltd. After two days, we started to observe 
the first crystals in many conditions of the JCSG-plus screen, with the best crystals growing 








Figure 4.10. Crystals of PKM2_K422E mutant. Crystals of PKM2_K422E grown by sitting drop 
vapor diffusion. The protein sample at 5 mg/ml was mixed with 10 mM Hepes pH 7.5, 100 mM KCl, 
5 mM MgCl2, 5% glycerol, 1 mM DTT, the same buffer conditions used for the WT protein. a B-04 
condition of the JCSG-plus HT-96 MD1-40 screen containing 0.1 M HEPES pH 7.5, 10% PEG 8000 
and 8% ethylene glycol. b C-04 condition of the same JCSG-plus screen containing 0.1 M HEPES 
pH7.0 and 10% PEG 6000. 
 
 
Unfortunately, none of the obtained single crystals diffracted during the X-ray diffraction 
analysis. Thus, I started to optimize the crystallization conditions manually with the hanging 
drop method. I used the conditions where the best crystals grew as a starting point to set up 
grid screens where we tested various concentrations of PKM2_422E protein and 
PKM2_K422E+Oleic acid and different buffer conditions. To further increase the 
percentage of success of the crystallization procedure and to work with a more reproducible 
system, I also performed seeding. In this case, crystals can be originated by seeds added to 
the equilibrating drops and this process can help to obtain larger single crystals.  
Seeding was always performed 24 hours after the preparation of the trays and we observed 
a higher efficiency of crystallization in the seeded wells (Figure 4.11).    
Sample concentration is a key factor for protein crystallization. PKM2 high concentrations 
have been shown to correlate with an increase in the tetramer formation in both the wild type 
and the mutants previously described (206). In order to avoid a concentration related 
configuration, we used the same concentration for both the WT and the K422E mutant 
corresponded to 5 mg/ml. Among the several conditions screened, we tested different 
concentrations of PEG-3350 (from 17% to 23%) and di-ammonium tartrate (from 225 mM 
to 275 mM). Moreover, we also added different additives commonly used to favor the 




Figure 4.11. PKM2_K422E crystals growing on seeding lines. Representative images acquired 
after seven days from the seeding process. Streak seeding was performed using micro-seeds obtained 
by pre-formed crystals previously crushed to be used as a seed stock. A cat whisker was used as a 
transfer tool for the seeds.    
 
 
PKM2 crystals morphology appeared to be highly modulated by additive concentration. 
Single crystals suitable for diffraction studies were obtained in the presence of different 
concentration of PEG-3350, glycine and proline (Figure 4.12).  
Crystals were harvested and flash cooled in liquid nitrogen in a cryo-protectant solution 
containing 20% glycerol and their X-ray diffraction was collected at beamline X06DA 
(PXIII) of the Swiss Light Source synchrotron (Villigen, Switzerland).  
 
 
Figure 4.12. PKM2_K422E crystals. PKM2_K422E crystals obtained after 7 days using the 
hanging drop method. a Crystals grown in the presence of 18% PEG-3350, 275 mM di-ammonium 







Despite obtaining single crystals suitable for diffraction for both PKM2_K422E and 
PKM2_K422E+Oleic acid, diffracting crystals were obtained only with protein incubated 
with Oleic acid. Hence, I focused exclusively on the refinement of the crystals grew in the 
presence of oleic acid. We were able to collect data for crystals belonging to two different 
space groups: P1 and P21, which diffracted with resolution limits of 1.89 and 2.00 Å, 
respectively. The P1 crystal grew in presence of 18% PEG-3350 and 7% phenol, 0.8 mM 
Oleic acid, while the P21 crystal grew in 10% PEG-3350 and 16% Glycine and 0.8 mM Oleic 
acid. The structures were solved by molecular replacement by our collaborators of the 
Biochemistry and Structural Biology Unit of the IEO, and refinement is still ongoing. Table 
5 reports the data collection statistics and the current state of model refinement. 
 
Table 5. Data collection and refinement statistics for PKM2 WT and the two PKM2_K422E crystal structures.
PKM2 wild type PKM2 K422E PKM2 K422E
Data Collection
Space group P21 P1 P21
Wavelength 1.00 1.00 1.00 
Cell dimensions
    a, b, c ( )
    , ,  (°)
81.28, 152.85, 94.10 





Resolution 70.32-2.87 (2.92-2.87) 118.89-1.89 (1.92-1.89) 161.73-2.00 (2.03-2.00)
Rsym or Rmerge 0.084 (0.701) 0.097 (0.994) 0.179 (2.962)
CC1/2 0.996 (0.749) 0.988 (0.169) 0.997 (0.356)
I/ I 11.7 (2.1) 4.1 (0.2) 4.9 (0.2)
Completeness (%) 99.0 (100.0) 97.7 (96.3) 100.0 (100.0)
Unique reflections 50586 (2549) 335311 (16522) 147132 (7324)
Multiplicity 4.2 (4.3) 3.4 (3.4) 6.6 (6.8)
Refinement
Resolution ( ) 45.85-2.87 53.19-1.89 91.52-2.00
Rwork/Rfree 0.343/0.376 0.213/0.238 0.230/0.280
No. atoms
    Proteins







B-factor protein/water 85.51/30.00 45.20/43.14 62.39/49.22
R.m.s. deviations
    Bond lengths ( )








    Favoured (%)
    Allowed (%)











The structures of PKM2_K422E in two different space groups are both arranged in the 
crystal packing as tetramers. However, two very different tetrameric assemblies are formed 
(see below). Indeed, the dimers assembling the two space groups are very different (Figure 
4.13), suggesting that the dimeric arrangement of PKM2_K422E is very open and allows a 
fairly large movement of one monomer with respect to the other.    
 
Figure 4.13. Structural comparison of PKM2 K422E crystals belonging to two different space 
groups. Superimposed crystal structures of the dimeric units of PKM2_K422E belonging to the P1 




In order to understand whether the different conformations assumed by the K422E mutant 
could correlate with the previously described T and R-states, we superposed the two crystal 
structures with two different PKM2 structures previously shown as T (PDB: 4QGC) and R-
state (PDB: 4RPP). The comparison showed us that PKM2_K422E P1 structure corresponds 
to the R-state, while the P21 structure, instead, matches with the T-state (Figure 4.14). 
Interestingly, while preliminary data suggests that the allosteric activator FPB is present in 
our WT structure, no density for FBP was observed in either the K422E structures. This 
suggests that, unlike the situation described for other mutants, with this mutant FBP is 
dispensable for R (active) state assembly. These observations open new perspectives for the 
study of the dimeric form of PKM2 enzyme that plays an important role in cancer 











Figure 4.14. Structural comparison of PKM2 K422E P1 and P21 crystals with PKM2 in R and 
T-states. Superimposed crystal structures of the dimeric units of PKM2_K422E belonging to the P1 
space group (left) with PKM2 R-state (PDB: 4RPP) respectively in orange and beige. On the right 
superimposed crystal structures of PKM2_K422E belonging to the P21 space group with PKM2 T-







































































Deregulation of lipid metabolism belongs to a more general metabolic reprogramming that 
is often observed in cancer cells that is required to satisfy the increased energy demands. 
Due to the important role dysregulated metabolism plays in supporting cell proliferation and 
cancer progression, there is an emergent interest in understanding the molecular mechanisms 
leading to the reprogramming.  
Recent studies highlighted the role of lipid metabolism in the maintenance of stemness 
properties in cancer cells. Cancer stem cells (CSC) represent a small percentage of the 
tumour mass and are characterized by high self-renewal capacity and tumour-initiating 
features. Importantly, they are considered to be refractory to most therapeutic treatments, 
thus an important target for effective therapeutic intervention. Interestingly, a recent 
metabolomic profiling of CSC has shown that CSC have specific metabolic alterations (151), 
particularly in lipid biosynthesis. Thus, a better understanding of the aberrant lipid 
metabolism could provide a strategy to better tackle this sub-population of cancer cells.  
An accumulation of lipid droplets in the subpopulation of cells that survived therapeutic 
intervention, the so-called minimal residual disease, has recently been described (179). Lipid 
droplets (LD) are cytosolic organelles constituted by triacyclglycerols and sterol esters 
surrounded by a phospholipidic monolayer. LDs number varies in response to the metabolic 
profile of the cells and the accumulation of LDs has been observed in many diseases, 
including cancer. Despite that, very little is known about the role of their accumulation in 
cancer onset and progression. Considering the important contribution of CSC to tumour 
progression (177) and the recent evidence that they have an aberrant lipid metabolic profile, 
I investigated whether there was any correlation between the accumulation of lipid droplets 
and stemness traits in breast cancer.  
Initially, I searched for a possible correlation between the expression of one of the most 
abundant lipid droplet associated proteins, PLIN2, and relapse free survival (R.F.S.) in breast 
cancer patients. Using Kaplan-Meyer plotter, I scored a significant negative correlation 
between PLIN2 expression and R.F.S., suggesting a potential role of lipid droplets 
accumulation and a worse clinical outcome.  
Analysing the LDs content of four different cell lines, I observed a remarkable heterogeneity 
both among the different cell lines and, surprisingly, also in the context of the same cell line, 
with some cells highly enriched in LDs while others were almost devoid. In regards to the 
observed differences in LD content between the cell lines could be explained by the different 
metabolic profiles of the four cell lines. Intriguingly these differences persist despite their 
being grown and maintained in the same media conditions. The differences observed in the 
same cell line, instead, could be explained by the intra-tumoural heterogeneity that has been 
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recently shown in cancer cell lines (207) and could be a sign of metabolically different clones 
inside the same population.  
Taking advantage of the in vitro approach developed to identify CSC that relies on their 
capability to survive form spheroids in non-adherent conditions (192), I observed that all the 
cell lines were able to form mammospheres, even if with a different efficiency. Importantly, 
a higher efficiency was observed in BT474 and MDA-MB-231, the cell lines most enriched 
for LDs, suggesting a possible correlation between LD accumulation and stemness. 
Moreover, in the second generation mammospheres, I observed, using confocal microscopy, 
that in the context of the single mammosphere, only one or two cells were highly enriched 
in LDs. Taken together, I could speculate that the cells which are highly enriched for LDs 
could represent the potential stem/progenitor cells. While the intracellular heterogeneity in 
the lipid droplets content could be associated with a more general cellular heterogeneity.  
Through the FACS-based method that we established to isolate the different subpopulations 
of cells according to the lipid droplets content, I demonstrated that the LD enriched 
subpopulation was indeed characterized by stem cell traits as shown by the higher expression 
of stemness markers, the higher propensity to form mammospheres and the colocalization 
in the FACS analysis with the CD44high/CD24low cells. All together these data demonstrated 
that the lipid droplets enriched sub-population of cells show a stem-like phenotype that is 
not shared with the LDlow population. Similar observations have been previously shown in 
colon-rectal cancer and glioblastoma (173, 175), suggesting a conserved common 
mechanism among different cancer types. 
Moreover, using xenotransplantation, I observed a higher tumorigenic potential of lipid 
droplets enriched cells that, when injected in mice, had an earlier onset in comparison to the 
LDlow cells. I can hypothesize that the accumulation of lipid droplets can have a role in breast 
cancer onset, confirming the important role of these organelles already described in other 
tumour types. Although the general implications of LDs accumulation in breast CSC require 
further investigation, I can postulate that LDs enrichment represents an important energy 
reservoir that can allow cells to survive under nutrient deprivation, as previously shown in 
colon cancer (208).  
Another interesting aspect of my study is that I provide evidence that LD enriched 
subpopulations of cells have an increased cytosolic complexity that is detectable in a label 
free manner by evaluating the SSC at FACS. This important aspect can be used as a new 
parameter to distinguish and isolate cancer stem cells from the population, providing a new 
tool for clinical diagnosis.  
As a further demonstration of the role played by lipid droplets, I provide evidence that 
targeting lipid droplets formation negatively impact upon cellular proliferation and 
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tumorigenesis in breast cancer cells. Despite the lack of specific LDs inhibitors, many 
chemical compounds targeting lipid metabolic pathways have been shown to affect LD 
formation (209). Among them, the Acetyl CoA Carboxylase alpha (ACC-alpha) chemical 
inhibitor TOFA (5-tetradecyloxy-2-furoic acid) has been previously shown to induce 
apoptosis in lung and colon cancer cells through targeting the de novo fatty acids synthesis 
pathway (210). My data is in line with those previous observations, showing that also breast 
cancer cell lines proliferation is affected by TOFA treatment, suggesting an addiction to de 
novo fatty acid biosynthesis is a feature of tumours derived from multiple tissue types. 
Moreover, I also showed that in BT474 cells the inhibition of LDs formation leads to a 
decreased mammospheres formation efficiency, suggesting an effect on the stem-like 
phenotype of LDs enriched cells described before. Although further studies are required to 
better characterize the molecular mechanism underpinning the correlation between LD 
accumulation and stemness traits, the possibility that targeting lipid metabolism and LDs 
formation impact on tumorigenesis, open important scenarios for the development of new 
therapeutic strategies.   
Interestingly, my data showed that MDA-MB-231 cells, representing triple negative breast 
cancer, were not affected by TOFA treatment, being the only exception in our panel of breast 
cancer cell lines. Indeed, they did not show any decrease in the LD amount upon TOFA 
treatments compared to the control cells; additionally, proliferation rates and mammosphere 
formation capacity were not affected by the inhibition of ACC. These findings suggest that 
MDA-MB-231 cells could rely on compensatory mechanisms that sustain their lipid 
biosynthetic pathways.  
Lipid metabolic reprogramming is emerging as an important contributor to cancer onset and 
progression. This is not surprising, since lipids play a role in multiple aspects of the cellular 
physiology from energy storage, to the generation of the cellular membranes and as signaling 
molecules. An additional role for lipids as modulators of the activity and function of proteins 
and enzymes, is another key function of lipids. In the late 60s’, Randle and collaborators 
demonstrated for the first time an hormone independent mechanism by which lipid and 
glucose metabolism regulated each other according to their availability (71). The Randle 
cycle, also known as glucose-fatty acid cycle, provided a mechanistic explanation for the 
observed decrease in glycolysis when high levels of fatty acids are available. Reciprocally, 
the increased glycolysis in the presence of high glucose availability, leads to decreased fatty 
acid oxidation. Moreover, a decreased activity of some glycolytic enzymes, such as 
phosphofructokinase (PFK) and pyruvate kinase (PK), was also described to correlate with 
increased levels of citrate, an essential metabolite upstream of FA biosynthesis (69, 180). 
The inhibition of glycolytic enzymes activity means a shift of the cellular metabolism from 
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catabolism to anabolism, a mechanism that is very often observed in cancer cells. Indeed, 
the enhanced tumour proliferation rates require an intense production of nucleic acids, 
proteins and lipids that is sustained by the carbon sources provided by the glycolytic 
intermediates such as glucose-6-phosphate and 3-phosphoglycerate (211). Despite the 
increased interest in the field, there are still many gaps in the understanding of the cross talk 
between lipid and glycolytic metabolism. 
In this study, I focused on the role of lipids as possible regulators of glycolysis and glycolytic 
enzymes opening new perspectives for this old field. Several studies have previously 
suggested a role for free fatty acids and lipids as regulators of glycolytic enzymes. 
Particularly, this was proposed for pyruvate kinase whose inhibition was reported to be 
regulated by long and short chain fatty acids as described by Weber and collaborators (72, 
200). These controversial studies done over 50 years ago described the potential for 
regulation but did not go as far as to describe a mechanism behind this phenomenon. More 
recently, quantitative mass spectrometry analysis of fatty acid associated proteins revealed 
that PKM2 was able to bind Palmitic acid, suggesting an interaction between the two as a 
possible mechanism of protein stabilization or re-localization, since palmitic acid represents 
one of the most abundant fatty acids in the cellular membranes (184). Given the 
aforementioned observations, I hypothesized that fatty acids themselves, might directly 
regulate Pyruvate kinase M2 (PKM2) activity by acting as an allosteric modulator of the 
protein. Pyruvate kinase catalyzes the terminal reaction of glycolysis and, as such, is 
believed to be one of the key regulators of glycolytic flux. While normal tissues express 
Pyruvate kinase M1 isoform, most tumours express the M2 isoform that arises from 
alternative splicing of one exon. Whereas PKM1 is constitutively active, PKM2 is 
allosterically regulated allowing for more efficient regulation of glycolytic flux. Therefore, 
I began by analyzing the expression and the activity of PKM2, in a panel of ten breast cancer 
cell lines. Although, I found similar levels of expression, the enzymatic activity of PKM2 
differed significantly between the 10 lines, suggesting an additional layer of regulation.  
Intrigued by these observations, I decided to analyze PKM2 aminoacidic sequence to better 
understand if it was possible an interaction with hydrophobic lipids. The hydropathy plot of 
PKM2 aminoacidic sequence, highlighted a region particularly enriched in hydrophobic 
residues that could be involved in the protein-lipids interaction. Performing a fatty acid pull-
down assay with cellular lysates using, as a bait, agarose beads coupled with fatty acids of 
different lengths and saturation states, I detected by western blot a strong interaction between 
PKM2 and all fatty acids tested. This interaction was maintained when the bacterial 
produced recombinant human PKM2 protein (rPKM2) was used in the place of whole cell 
lysates, suggesting a direct interaction between the PKM2 protein and fatty acids.  
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I noticed that although the rPKM2 bound the fatty acids, the binding efficiency appeared to 
be lower compared to that from the lysates, therefore I decided to further analyze the 
sequence to try to gain additional insight into the binding. Comparing the information 
retrieved by the hydropathy plot with the previously resolved PKM2 crystal structure, I 
realized that the region of the protein characterized by an enrichment in hydrophobic 
residues localized to the inter-subunit contact domain. This was not unexpected if we 
consider that proteins usually fold in the most thermodynamically stable state in which, 
hydrophilic regions are exposed to the polar environment and hydrophobic portions are 
instead enclosed within water-free domains. But, the most interesting aspect of this 
observation was that those hydrophobic alpha-helixes that mapped to the inter-subunit 
contact domain represent the contact site where two dimers of PKM2 interact to form the 
tetrameric form of PKM2 that is active in glycolysis. In contrast to PKM1 which is 
constitutively active, PKM2 activity is allosterically regulated. Thus, regulating the 
conversion between the dimeric (putative protein kinase) and tetrameric (glycolytic) forms 
of PKM2. Cells use this mechanism to tune the glycolytic flux according to the specific 
circumstances (212). Considering that within a cellular context PKM2 is found both in 
dimeric and tetrameric forms, I hypothesized that the dimer may be the lipid interacting form 
of PKM2.   
In order to test this hypothesis, I generated and characterized a set of bacterially produced 
PKM2 mutants. This characterization revealed lysine K422 as a key residue in regulating 
tetramer formation. Indeed, replacement of the Lysine with Glutamic Acid resulted in the 
production of a stable dimer as demonstrated by SLS. Performing lipid binding assays using 
the recombinant wildtype and dimeric form of PKM2, I demonstrated that dimeric PKM2 
bound fatty acids with a higher affinity than the tetrameric protein. Excitingly, these results 
suggest a potential role of fatty acids as modulators of PKM2 structure and activity, opening 
new scenarios for the understanding of the complex allosteric regulation of PKM2 enzyme.  
The idea of fatty acids as allosteric regulators was also recently proposed by Pinkosky and 
colleagues, who demonstrated that long-chain fatty acyl-CoA regulate AMPK activity (213) 
(214). In this case fatty acyl-CoA binding activates AMPK leading to phosphorylation and 
inactivation of ACC1, thus contributing to AMPK mediated metabolic reprograming. This 
work provides further evidence that fatty acid binding participates in metabolic 
reprogramming by tuning enzyme activity.  
My next goal was to understand whether structural studies could help me to better 
characterize the hypothetical fatty acid binding site in my PKM2_K422E dimer. In an 
attempt to identify the residues that coordinate the fatty acyl binding, all crystallization trials 
were done in the presence of oleic acid. Initial structural analysis revealed that, despite 
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purifying as a dimer, the PKM2 K422E mutant crystalized as a tetramer. Regardless, 
structural studies of PKM2_K422E mutant revealed that, in comparison with the wild type 
protein, the mutant could assemble into two different conformations, corresponding with the 
previously published active (R) and inactive state (T). Interestingly, the ability to form the 
R state has previously been described to require the binding of FBP, yet I found no evidence 
for an FBP density in the refined structures. Suggesting that this mutant is able to form an 
active state in the absence of FBP. Further studies are ongoing to confirm its ability to 
catalyze the conversion of PEP to pyruvate. The ability of the dimer to form these two 
tetrameric assemblies suggests that, with respect to the wildtype, the dimeric arrangement 
of PKM2_K422E is more fluid, and allows movement of one monomer with respect to the 
other. Despite the presence of Oleic acid during the crystallization, I was not able to detect 
a density for oleic acid in the refined structure. Yet, interestingly, although I also sent crystals 
of PKM2_K422E formed in the absence of oleic acid for diffraction analysis, they were 
unable to diffract. Collectively, this data suggests that the presence of oleic acid could 
stabilize the structure of PKM2_K422E, since in its absence, I do not obtain ordered 
structures able to diffract. The absence of oleic acid density in my crystals of course 
represents an important aspect to consider. It is a well-recognized concept that fatty acids in 
solution tend to form micelles, changing their chemical properties, for this reason it’s usually 
not possible to use concentrations higher than 0.5-1 mM since this aspect can interfere with 
the formation of the complex protein-fatty acid. Previous studies have shown that these low 
concentrations used for fatty acid binding protein crystallization trials might have been too 
low to allow the detection of the presence of fatty acid electron density (215).  
In this study, taking advantage of in vitro assays, I showed that medium and long-chain fatty 
acids can bind the glycolytic gatekeeper PKM2. Moreover, preliminary data from my 
structural investigation, suggested that fatty acids can regulate the dimer/tetramer transition, 
acting as allosteric regulator. While further functional and crystallization studies are 
ongoing, my findings pave the way towards uncovering fatty acids as a novel regulator of 
PKM2 activity.  As direct regulators of glycolysis, fatty acids could have a direct role on the 
balance between catabolism and anabolism, which, together with the recent description of 
the role of fatty acids in regulating AMPK, add a new chapter in our knowledge of the 
cellular metabolism. The functional implications of this mechanism could be multiple, since 
the allosteric regulation of PKM2 plays an important role in cancer onset and progression. 
One could speculate that the metabolic reprogramming observed in cancer could include 
another level of complexity connecting the highly active de novo fatty acid synthesis with 
the regulation of PKM2 activity, considered a fundamental player in cancer metabolism. The 
binding of lipids to PKM2 could lead to the stabilization of the dimer thus representing a 
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way to sustain the anabolic growth in cancer cells. Another possibility one could contemplate 
is the possible role of medium-long fatty acids as activators of PKM2. A recent study 
demonstrated a role of the short chain fatty acid butyrate in promoting PKM2 
tetramerization, thus inhibiting the Warburg effect and proliferation of colon-rectal cancer 
cells (216). Although the exact mechanism is still not understood, my findings open new 
perspectives on the role of lipid metabolism in the regulation of the cellular proliferation and 
cancer progression.  
Multiple studies have demonstrated an upregulation of PKM2 in solid tumours, including 
breast (217), liver (218) and colon-rectal cancers (219), as well as a role for PKM2 in 
therapeutic resistance (220), suggesting that it could be a viable therapeutic target. Among 
the different regulators of glycolysis or PKM2 inhibitors introduced into the clinics, 
including Metformin (221) and Temozolomide (222),  Shikonin represents a good candidate 
due to the high specificity towards PKM2 (223). Yet, it has limited success due to reported 
high toxicity and low solubility (224). Thus, the identification of effective to modulate 
PKM2 activity in cancer represents an unmet clinical need. Due to the interplay between 
glucose and lipid metabolism, we could target the main lipid metabolic pathways, thus 
impacting indirectly the glycolytic flux by regulating both PKM2 and AMPK activity. For 
example, as already shown in cortical neurons, the use of C75, a specific Fatty acid synthase 
(FASN) inhibitor, has an impact on glucose metabolism (225). Moreover, the use of the 
antibiotic Platensimycin, another inhibitor of FASN, has also shown to induce an increase 
of glucose oxidation in mouse models of diabetes (226). High levels of free fatty acids have 
been described in breast cancer (227) as key players of the metabolic reprogramming of 
cancer cells. Thus, a better characterization of their role in the regulation of the glycolytic 
flux could open the avenue towards the development of new therapeutic strategies since the 
use of specific lipid metabolic inhibitors in cancer therapy could also impact on the 














1. H. Sung et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence 
and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 
10.3322/caac.21660 (2021). 
2. M. Escala-Garcia et al., Breast cancer risk factors and their effects on survival: a 
Mendelian randomisation study. BMC Med 18, 327 (2020). 
3. I. Alvarado Cabrero, M. Carrera Alvarez, D. Perez Montiel, F. A. Tavassoli, 
Metastases to the breast. Eur J Surg Oncol 29, 854-855 (2003). 
4. J. Ferlay et al., Cancer incidence and mortality worldwide: sources, methods and 
major patterns in GLOBOCAN 2012. Int J Cancer 136, E359-386 (2015). 
5. A. Goldhirsch et al., Strategies for subtypes--dealing with the diversity of breast 
cancer: highlights of the St. Gallen International Expert Consensus on the Primary 
Therapy of Early Breast Cancer 2011. Ann Oncol 22, 1736-1747 (2011). 
6. P. J. O'Donovan, D. M. Livingston, BRCA1 and BRCA2: breast/ovarian cancer 
susceptibility gene products and participants in DNA double-strand break repair. 
Carcinogenesis 31, 961-967 (2010). 
7. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: the next generation. Cell 144, 
646-674 (2011). 
8. M. M. Zarou, A. Vazquez, G. Vignir Helgason, Folate metabolism: a re-emerging 
therapeutic target in haematological cancers. Leukemia 10.1038/s41375-021-01189-
2 (2021). 
9. S. Ali, R. C. Coombes, Endocrine-responsive breast cancer and strategies for 
combating resistance. Nat Rev Cancer 2, 101-112 (2002). 
10. D. Zhang et al., Proteomic study reveals that proteins involved in metabolic and 
detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. 
Mol Cell Proteomics 4, 1686-1696 (2005). 
11. Y. H. Zhao et al., Upregulation of lactate dehydrogenase A by ErbB2 through heat 
shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene 28, 
3689-3701 (2009). 
12. L. Shen et al., Metabolic reprogramming in triple-negative breast cancer through 
Myc suppression of TXNIP. Proc Natl Acad Sci U S A 112, 5425-5430 (2015). 
13. J. O'Neal et al., Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses 
glucose metabolism and the growth of HER2+ breast cancer. Breast Cancer Res 
Treat 160, 29-40 (2016). 
14. Y. Zhao et al., Overcoming trastuzumab resistance in breast cancer by targeting 
dysregulated glucose metabolism. Cancer Res 71, 4585-4597 (2011). 
15. D. S. Wishart, Is Cancer a Genetic Disease or a Metabolic Disease? EBioMedicine 
2, 478-479 (2015). 
16. O. Warburg, F. Wind, E. Negelein, The Metabolism of Tumors in the Body. J Gen 
Physiol 8, 519-530 (1927). 
17. M. G. Vander Heiden, L. C. Cantley, C. B. Thompson, Understanding the Warburg 
effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 
(2009). 
18. N. N. Pavlova, C. B. Thompson, The Emerging Hallmarks of Cancer Metabolism. 
Cell Metab 23, 27-47 (2016). 
19. R. J. DeBerardinis, N. S. Chandel, Fundamentals of cancer metabolism. Sci Adv 2, 
e1600200 (2016). 
20. O. Warburg, On the origin of cancer cells. Science 123, 309-314 (1956). 
21. N. Majewski et al., Hexokinase-mitochondria interaction mediated by Akt is 
required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16, 
819-830 (2004). 
 88 
22. S. P. Mathupala, Y. H. Ko, P. L. Pedersen, Hexokinase II: cancer's double-edged 
sword acting as both facilitator and gatekeeper of malignancy when bound to 
mitochondria. Oncogene 25, 4777-4786 (2006). 
23. K. C. Patra et al., Hexokinase 2 is required for tumor initiation and maintenance and 
its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24, 213-
228 (2013). 
24. X. Y. Zhang et al., Hexokinase 2 confers resistance to cisplatin in ovarian cancer 
cells by enhancing cisplatin-induced autophagy. Int J Biochem Cell Biol 95, 9-16 
(2018). 
25. A. Wolf et al., Hexokinase 2 is a key mediator of aerobic glycolysis and promotes 
tumor growth in human glioblastoma multiforme. J Exp Med 208, 313-326 (2011). 
26. T. Atsumi et al., High expression of inducible 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 62, 5881-5887 
(2002). 
27. S. Mazurek, Pyruvate kinase type M2: a key regulator of the metabolic budget system 
in tumor cells. Int J Biochem Cell Biol 43, 969-980 (2011). 
28. M. S. Jurica et al., The allosteric regulation of pyruvate kinase by fructose-1,6-
bisphosphate. Structure 6, 195-210 (1998). 
29. W. J. Israelsen et al., PKM2 isoform-specific deletion reveals a differential 
requirement for pyruvate kinase in tumor cells. Cell 155, 397-409 (2013). 
30. T. Noguchi, H. Inoue, T. Tanaka, The M1- and M2-type isozymes of rat pyruvate 
kinase are produced from the same gene by alternative RNA splicing. J Biol Chem 
261, 13807-13812 (1986). 
31. C. V. Clower et al., The alternative splicing repressors hnRNP A1/A2 and PTB 
influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad 
Sci U S A 107, 1894-1899 (2010). 
32. C. J. David, M. Chen, M. Assanah, P. Canoll, J. L. Manley, HnRNP proteins 
controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 
463, 364-368 (2010). 
33. B. Chaneton, E. Gottlieb, Rocking cell metabolism: revised functions of the key 
glycolytic regulator PKM2 in cancer. Trends Biochem Sci 37, 309-316 (2012). 
34. J. D. Dombrauckas, B. D. Santarsiero, A. D. Mesecar, Structural basis for tumor 
pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44, 9417-9429 
(2005). 
35. H. R. Christofk et al., The M2 splice isoform of pyruvate kinase is important for 
cancer metabolism and tumour growth. Nature 452, 230-233 (2008). 
36. S. Mazurek, W. Zwerschke, P. Jansen-Durr, E. Eigenbrodt, Effects of the human 
papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of 
pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem J 356, 247-
256 (2001). 
37. T. L. Dayton, T. Jacks, M. G. Vander Heiden, PKM2, cancer metabolism, and the 
road ahead. EMBO Rep 17, 1721-1730 (2016). 
38. K. E. Keller, I. S. Tan, Y. S. Lee, SAICAR stimulates pyruvate kinase isoform M2 
and promotes cancer cell survival in glucose-limited conditions. Science 338, 1069-
1072 (2012). 
39. E. Eigenbrodt, D. Basenau, S. Holthusen, S. Mazurek, G. Fischer, Quantification of 
tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res 
17, 3153-3156 (1997). 
40. D. Anastasiou et al., Pyruvate kinase M2 activators promote tetramer formation and 
suppress tumorigenesis. Nat Chem Biol 8, 839-847 (2012). 
41. G. M. Oremek, S. Teigelkamp, W. Kramer, E. Eigenbrodt, K. H. Usadel, The 
pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal 
carcinoma. Anticancer Res 19, 2599-2601 (1999). 
 89 
42. G. M. Oremek, E. Eigenbrodt, J. Radle, S. Zeuzem, U. B. Seiffert, Value of the serum 
levels of the tumor marker TUM2-PK in pancreatic cancer. Anticancer Res 17, 3031-
3033 (1997). 
43. H. Cerwenka et al., TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA 
in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer 
Res 19, 849-851 (1999). 
44. Q. Sun et al., Mammalian target of rapamycin up-regulation of pyruvate kinase 
isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl 
Acad Sci U S A 108, 4129-4134 (2011). 
45. K. E. Keller, Z. M. Doctor, Z. W. Dwyer, Y. S. Lee, SAICAR induces protein kinase 
activity of PKM2 that is necessary for sustained proliferative signaling of cancer 
cells. Mol Cell 53, 700-709 (2014). 
46. W. Ying, NAD+/NADH and NADP+/NADPH in cellular functions and cell death: 
regulation and biological consequences. Antioxid Redox Signal 10, 179-206 (2008). 
47. R. Possemato et al., Functional genomics reveal that the serine synthesis pathway is 
essential in breast cancer. Nature 476, 346-350 (2011). 
48. G. M. DeNicola et al., NRF2 regulates serine biosynthesis in non-small cell lung 
cancer. Nat Genet 47, 1475-1481 (2015). 
49. X. Gao, H. Wang, J. J. Yang, X. Liu, Z. R. Liu, Pyruvate kinase M2 regulates gene 
transcription by acting as a protein kinase. Mol Cell 45, 598-609 (2012). 
50. L. Lv et al., Mitogenic and oncogenic stimulation of K433 acetylation promotes 
PKM2 protein kinase activity and nuclear localization. Mol Cell 52, 340-352 (2013). 
51. W. Yang et al., ERK1/2-dependent phosphorylation and nuclear translocation of 
PKM2 promotes the Warburg effect. Nat Cell Biol 14, 1295-1304 (2012). 
52. X. Gao et al., Reciprocal regulation of protein kinase and pyruvate kinase activities 
of pyruvate kinase M2 by growth signals. J Biol Chem 288, 15971-15979 (2013). 
53. W. Yang et al., PKM2 phosphorylates histone H3 and promotes gene transcription 
and tumorigenesis. Cell 150, 685-696 (2012). 
54. S. R. Hwang et al., Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-
dependent phosphorylation of signal transducer and activator of transcription 3 and 
oncogenesis in anaplastic large cell lymphoma. Lab Invest 97, 962-970 (2017). 
55. P. Yang, Z. Li, R. Fu, H. Wu, Z. Li, Pyruvate kinase M2 facilitates colon cancer cell 
migration via the modulation of STAT3 signalling. Cell Signal 26, 1853-1862 
(2014). 
56. W. Yang et al., Nuclear PKM2 regulates beta-catenin transactivation upon EGFR 
activation. Nature 480, 118-122 (2011). 
57. J. Lee, H. K. Kim, Y. M. Han, J. Kim, Pyruvate kinase isozyme type M2 (PKM2) 
interacts and cooperates with Oct-4 in regulating transcription. Int J Biochem Cell 
Biol 40, 1043-1054 (2008). 
58. W. Luo et al., Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-
inducible factor 1. Cell 145, 732-744 (2011). 
59. Y. Ikeda, T. Noguchi, Allosteric regulation of pyruvate kinase M2 isozyme involves 
a cysteine residue in the intersubunit contact. J Biol Chem 273, 12227-12233 (1998). 
60. K. Ashizawa, M. C. Willingham, C. M. Liang, S. Y. Cheng, In vivo regulation of 
monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated 
via fructose 1,6-bisphosphate. J Biol Chem 266, 16842-16846 (1991). 
61. E. Bailey, F. Stirpe, C. B. Taylor, Regulation of rat liver pyruvate kinase. The effect 
of preincubation, pH, copper ions, fructose 1,6-diphosphate and dietary changes on 
enzyme activity. Biochem J 108, 427-436 (1968). 
62. A. Dabrowska, J. Pietkiewicz, K. Dabrowska, E. Czapinska, R. Danielewicz, 
Interaction of M1 and M2 isozymes pyruvate kinase from human tissues with 
phospholipids. Biochim Biophys Acta 1383, 123-129 (1998). 
 90 
63. G. Sparmann, J. Schulz, E. Hofmann, Effects of L-alanine and fructose (1,6-
diphosphate) on pyruvate kinase from ehrlich ascites tumour cells. FEBS Lett 36, 
305-308 (1973). 
64. B. Chaneton et al., Serine is a natural ligand and allosteric activator of pyruvate 
kinase M2. Nature 491, 458-462 (2012). 
65. H. P. Morgan et al., M2 pyruvate kinase provides a mechanism for nutrient sensing 
and regulation of cell proliferation. Proc Natl Acad Sci U S A 110, 5881-5886 (2013). 
66. T. Hitosugi et al., Tyrosine phosphorylation inhibits PKM2 to promote the Warburg 
effect and tumor growth. Sci Signal 2, ra73 (2009). 
67. D. Anastasiou et al., Inhibition of pyruvate kinase M2 by reactive oxygen species 
contributes to cellular antioxidant responses. Science 334, 1278-1283 (2011). 
68. L. Lv et al., Acetylation targets the M2 isoform of pyruvate kinase for degradation 
through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 42, 
719-730 (2011). 
69. P. B. Garland, D. Shepherd, D. G. Nicholls, J. Ontko, Energy-dependent control of 
the tricarboxylic acid cycle by fatty acid oxidation in rat liver mitochondria. Adv 
Enzyme Regul 6, 3-30 (1968). 
70. E. A. Newsholme, P. J. Randle, K. L. Manchester, Inhibition of the 
phosphofructokinase reaction in perfused rat heart by respiration of ketone bodies, 
fatty acids and pyruvate. Nature 193, 270-271 (1962). 
71. P. J. Randle, P. B. Garland, C. N. Hales, E. A. Newsholme, The glucose fatty-acid 
cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes 
mellitus. Lancet 1, 785-789 (1963). 
72. G. Weber, M. A. Lea, N. B. Stamm, Sequential feedback inhibition and regulation 
of liver carbohydrate metabolism through control of enzyme activity. Adv Enzyme 
Regul 6, 101-123 (1968). 
73. C. Depre, S. Ponchaut, J. Deprez, L. Maisin, L. Hue, Cyclic AMP suppresses the 
inhibition of glycolysis by alternative oxidizable substrates in the heart. J Clin Invest 
101, 390-397 (1998). 
74. N. H. Jeoung, R. A. Harris, Pyruvate dehydrogenase kinase-4 deficiency lowers 
blood glucose and improves glucose tolerance in diet-induced obese mice. Am J 
Physiol Endocrinol Metab 295, E46-54 (2008). 
75. A. P. Bhatt et al., Dysregulation of fatty acid synthesis and glycolysis in non-
Hodgkin lymphoma. Proc Natl Acad Sci U S A 109, 11818-11823 (2012). 
76. E. S. Reckzeh et al., Inhibition of Glucose Transporters and Glutaminase 
Synergistically Impairs Tumor Cell Growth. Cell Chem Biol 26, 1214-1228 e1225 
(2019). 
77. H. Lin et al., Fatty acid oxidation is required for the respiration and proliferation of 
malignant glioma cells. Neuro Oncol 19, 43-54 (2017). 
78. J. A. Menendez, R. Lupu, Fatty acid synthase regulates estrogen receptor-alpha 
signaling in breast cancer cells. Oncogenesis 6, e299 (2017). 
79. J. V. Swinnen et al., Overexpression of fatty acid synthase is an early and common 
event in the development of prostate cancer. Int J Cancer 98, 19-22 (2002). 
80. W. Zhao et al., Fatty acid synthase: a novel target for antiglioma therapy. Br J Cancer 
95, 869-878 (2006). 
81. D. Innocenzi et al., Fatty acid synthase expression in melanoma. J Cutan Pathol 30, 
23-28 (2003). 
82. J. V. Swinnen, K. Brusselmans, G. Verhoeven, Increased lipogenesis in cancer cells: 
new players, novel targets. Curr Opin Clin Nutr Metab Care 9, 358-365 (2006). 
83. C. Postic, J. Girard, The role of the lipogenic pathway in the development of hepatic 
steatosis. Diabetes Metab 34, 643-648 (2008). 
84. Q. Liu, Q. Luo, A. Halim, G. Song, Targeting lipid metabolism of cancer cells: A 
promising therapeutic strategy for cancer. Cancer Lett 401, 39-45 (2017). 
 91 
85. N. Koundouros, G. Poulogiannis, Reprogramming of fatty acid metabolism in 
cancer. Br J Cancer 122, 4-22 (2020). 
86. E. Audet-Walsh et al., SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis 
in Prostate Cancer. Mol Cancer Res 16, 1396-1405 (2018). 
87. G. Lee et al., Post-transcriptional Regulation of De Novo Lipogenesis by mTORC1-
S6K1-SRPK2 Signaling. Cell 171, 1545-1558 e1518 (2017). 
88. H. Q. Wang et al., Positive feedback regulation between AKT activation and fatty 
acid synthase expression in ovarian carcinoma cells. Oncogene 24, 3574-3582 
(2005). 
89. D. Guo et al., An LXR agonist promotes glioblastoma cell death through inhibition 
of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov 1, 442-456 
(2011). 
90. D. Guo et al., EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-
resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2, ra82 
(2009). 
91. R. A. Saxton, D. M. Sabatini, mTOR Signaling in Growth, Metabolism, and Disease. 
Cell 168, 960-976 (2017). 
92. T. Porstmann et al., SREBP activity is regulated by mTORC1 and contributes to Akt-
dependent cell growth. Cell Metab 8, 224-236 (2008). 
93. Y. Guri et al., mTORC2 Promotes Tumorigenesis via Lipid Synthesis. Cancer Cell 
32, 807-823 e812 (2017). 
94. A. Nath, I. Li, L. R. Roberts, C. Chan, Elevated free fatty acid uptake via CD36 
promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Sci Rep 5, 
14752 (2015). 
95. A. Ladanyi et al., Adipocyte-induced CD36 expression drives ovarian cancer 
progression and metastasis. Oncogene 37, 2285-2301 (2018). 
96. Z. Madak-Erdogan et al., Free Fatty Acids Rewire Cancer Metabolism in Obesity-
Associated Breast Cancer via Estrogen Receptor and mTOR Signaling. Cancer Res 
79, 2494-2510 (2019). 
97. E. Rysman et al., De novo lipogenesis protects cancer cells from free radicals and 
chemotherapeutics by promoting membrane lipid saturation. Cancer Res 70, 8117-
8126 (2010). 
98. R. Watanabe, L. Wei, J. Huang, mTOR signaling, function, novel inhibitors, and 
therapeutic targets. J Nucl Med 52, 497-500 (2011). 
99. D. Wang, R. N. Dubois, Eicosanoids and cancer. Nat Rev Cancer 10, 181-193 
(2010). 
100. L. L. Listenberger et al., Triglyceride accumulation protects against fatty acid-
induced lipotoxicity. Proc Natl Acad Sci U S A 100, 3077-3082 (2003). 
101. M. T. Accioly et al., Lipid bodies are reservoirs of cyclooxygenase-2 and sites of 
prostaglandin-E2 synthesis in colon cancer cells. Cancer Res 68, 1732-1740 (2008). 
102. R. V. Farese, Jr., T. C. Walther, Lipid droplets finally get a little R-E-S-P-E-C-T. 
Cell 139, 855-860 (2009). 
103. S. Yasuda et al., Gene polymorphisms of tissue plasminogen activator and 
plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies. J 
Rheumatol 29, 1192-1197 (2002). 
104. K. Tauchi-Sato, S. Ozeki, T. Houjou, R. Taguchi, T. Fujimoto, The surface of lipid 
droplets is a phospholipid monolayer with a unique Fatty Acid composition. J Biol 
Chem 277, 44507-44512 (2002). 
105. J. A. Olzmann, P. Carvalho, Dynamics and functions of lipid droplets. Nat Rev Mol 
Cell Biol 20, 137-155 (2019). 
106. M. J. Robenek et al., Lipids partition caveolin-1 from ER membranes into lipid 
droplets: updating the model of lipid droplet biogenesis. FASEB J 18, 866-868 
(2004). 
 92 
107. H. L. Ploegh, A lipid-based model for the creation of an escape hatch from the 
endoplasmic reticulum. Nature 448, 435-438 (2007). 
108. V. Choudhary, N. Jacquier, R. Schneiter, The topology of the triacylglycerol 
synthesizing enzyme Lro1 indicates that neutral lipids can be produced within the 
luminal compartment of the endoplasmatic reticulum: Implications for the biogenesis 
of lipid droplets. Commun Integr Biol 4, 781-784 (2011). 
109. V. Choudhary, N. Ojha, A. Golden, W. A. Prinz, A conserved family of proteins 
facilitates nascent lipid droplet budding from the ER. J Cell Biol 211, 261-271 
(2015). 
110. A. R. Thiam, L. Foret, The physics of lipid droplet nucleation, growth and budding. 
Biochim Biophys Acta 1861, 715-722 (2016). 
111. N. T. Nettebrock, M. Bohnert, Born this way - Biogenesis of lipid droplets from 
specialized ER subdomains. Biochim Biophys Acta Mol Cell Biol Lipids 1865, 
158448 (2020). 
112. P. R. Cullis, B. de Kruijff, Lipid polymorphism and the functional roles of lipids in 
biological membranes. Biochim Biophys Acta 559, 399-420 (1979). 
113. K. Ben M'barek et al., ER Membrane Phospholipids and Surface Tension Control 
Cellular Lipid Droplet Formation. Dev Cell 41, 591-604 e597 (2017). 
114. Y. Y. Zaytseva et al., Increased expression of fatty acid synthase provides a survival 
advantage to colorectal cancer cells via upregulation of cellular respiration. 
Oncotarget 6, 18891-18904 (2015). 
115. A. K. Cotte et al., Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet 
production supports colorectal cancer chemoresistance. Nat Commun 9, 322 (2018). 
116. B. Taib et al., Lipid accumulation and oxidation in glioblastoma multiforme. Sci Rep 
9, 19593 (2019). 
117. E. Clement et al., Adipocyte extracellular vesicles carry enzymes and fatty acids that 
stimulate mitochondrial metabolism and remodeling in tumor cells. EMBO J 39, 
e102525 (2020). 
118. Y. Y. Wang et al., Mammary adipocytes stimulate breast cancer invasion through 
metabolic remodeling of tumor cells. JCI Insight 2, e87489 (2017). 
119. E. Jarc et al., Lipid droplets induced by secreted phospholipase A2 and unsaturated 
fatty acids protect breast cancer cells from nutrient and lipotoxic stress. Biochim 
Biophys Acta Mol Cell Biol Lipids 1863, 247-265 (2018). 
120. A. Pucer et al., Group X secreted phospholipase A(2) induces lipid droplet formation 
and prolongs breast cancer cell survival. Mol Cancer 12, 111 (2013). 
121. C. Corbet et al., TGFbeta2-induced formation of lipid droplets supports acidosis-
driven EMT and the metastatic spreading of cancer cells. Nat Commun 11, 454 
(2020). 
122. A. M. Giudetti et al., A specific lipid metabolic profile is associated with the 
epithelial mesenchymal transition program. Biochim Biophys Acta Mol Cell Biol 
Lipids 1864, 344-357 (2019). 
123. H. J. Wright et al., CDCP1 drives triple-negative breast cancer metastasis through 
reduction of lipid-droplet abundance and stimulation of fatty acid oxidation. Proc 
Natl Acad Sci U S A 114, E6556-E6565 (2017). 
124. R. Gushima et al., Expression of adipophilin in gastric epithelial neoplasia is 
associated with intestinal differentiation and discriminates between adenoma and 
adenocarcinoma. Virchows Arch 468, 169-177 (2016). 
125. X. D. Zhang et al., Identification of adipophilin as a potential diagnostic tumor 
marker for lung adenocarcinoma. Int J Clin Exp Med 7, 1190-1196 (2014). 
126. M. Fujimoto et al., Adipophilin expression in cutaneous malignant melanoma. J 
Cutan Pathol 44, 228-236 (2017). 
127. K. Wang et al., PLIN3 is up-regulated and correlates with poor prognosis in clear 
cell renal cell carcinoma. Urol Oncol 36, 343 e349-343 e319 (2018). 
 93 
128. M. Fujimoto et al., Adipophilin expression in lung adenocarcinoma is associated 
with apocrine-like features and poor clinical prognosis: an immunohistochemical 
study of 328 cases. Histopathology 70, 232-241 (2017). 
129. M. Yao et al., Expression of adipose differentiation-related protein: a predictor of 
cancer-specific survival in clear cell renal carcinoma. Clin Cancer Res 13, 152-160 
(2007). 
130. A. Herms et al., AMPK activation promotes lipid droplet dispersion on detyrosinated 
microtubules to increase mitochondrial fatty acid oxidation. Nat Commun 6, 7176 
(2015). 
131. J. Zhu et al., Phosphorylation of PLIN3 by AMPK promotes dispersion of lipid 
droplets during starvation. Protein Cell 10, 382-387 (2019). 
132. B. Englinger et al., Lipid droplet-mediated scavenging as novel intrinsic and adaptive 
resistance factor against the multikinase inhibitor ponatinib. Int J Cancer 147, 1680-
1693 (2020). 
133. R. Dubey et al., Lipid droplets can promote drug accumulation and activation. Nat 
Chem Biol 16, 206-213 (2020). 
134. A. Carnero et al., The cancer stem-cell signaling network and resistance to therapy. 
Cancer Treat Rev 49, 25-36 (2016). 
135. M. Todaro et al., Colon cancer stem cells dictate tumor growth and resist cell death 
by production of interleukin-4. Cell Stem Cell 1, 389-402 (2007). 
136. R. Bjerkvig, B. B. Tysnes, K. S. Aboody, J. Najbauer, A. J. Terzis, Opinion: the 
origin of the cancer stem cell: current controversies and new insights. Nat Rev 
Cancer 5, 899-904 (2005). 
137. Y. Cho et al., Cleaved CD44 intracellular domain supports activation of stemness 
factors and promotes tumorigenesis of breast cancer. Oncotarget 6, 8709-8721 
(2015). 
138. J. Cui, P. Li, X. Liu, H. Hu, W. Wei, Abnormal expression of the Notch and 
Wnt/beta-catenin signaling pathways in stem-like ALDH(hi)CD44(+) cells 
correlates highly with Ki-67 expression in breast cancer. Oncol Lett 9, 1600-1606 
(2015). 
139. A. N. Seo et al., Expression of breast cancer stem cell markers as predictors of 
prognosis and response to trastuzumab in HER2-positive breast cancer. Br J Cancer 
114, 1109-1116 (2016). 
140. C. Joseph et al., Overexpression of the cancer stem cell marker CD133 confers a 
poor prognosis in invasive breast cancer. Breast Cancer Res Treat 174, 387-399 
(2019). 
141. C. Bock et al., Strong correlation between N-cadherin and CD133 in breast cancer: 
role of both markers in metastatic events. J Cancer Res Clin Oncol 140, 1873-1881 
(2014). 
142. F. Brugnoli et al., Up-modulation of PLC-beta2 reduces the number and malignancy 
of triple-negative breast tumor cells with a CD133(+)/EpCAM(+) phenotype: a 
promising target for preventing progression of TNBC. BMC Cancer 17, 617 (2017). 
143. T. Hiraga, S. Ito, H. Nakamura, EpCAM expression in breast cancer cells is 
associated with enhanced bone metastasis formation. Int J Cancer 138, 1698-1708 
(2016). 
144. C. Hadjimichael et al., Common stemness regulators of embryonic and cancer stem 
cells. World J Stem Cells 7, 1150-1184 (2015). 
145. D. Wang et al., Oct-4 and Nanog promote the epithelial-mesenchymal transition of 
breast cancer stem cells and are associated with poor prognosis in breast cancer 
patients. Oncotarget 5, 10803-10815 (2014). 
146. F. Yang, J. Zhang, H. Yang, OCT4, SOX2, and NANOG positive expression 
correlates with poor differentiation, advanced disease stages, and worse overall 
 94 
survival in HER2(+) breast cancer patients. Onco Targets Ther 11, 7873-7881 
(2018). 
147. C. Zhang, C. Li, F. He, Y. Cai, H. Yang, Identification of CD44+CD24+ gastric 
cancer stem cells. J Cancer Res Clin Oncol 137, 1679-1686 (2011). 
148. G. Mannelli, O. Gallo, Cancer stem cells hypothesis and stem cells in head and neck 
cancers. Cancer Treat Rev 38, 515-539 (2012). 
149. J. Dou, N. Gu, Emerging strategies for the identification and targeting of cancer stem 
cells. Tumour Biol 31, 243-253 (2010). 
150. M. Peiris-Pages, U. E. Martinez-Outschoorn, R. G. Pestell, F. Sotgia, M. P. Lisanti, 
Cancer stem cell metabolism. Breast Cancer Res 18, 55 (2016). 
151. M. Sun, Z. Yang, Metabolomic Studies of Live Single Cancer Stem Cells Using 
Mass Spectrometry. Anal Chem 91, 2384-2391 (2019). 
152. R. Mancini et al., Metabolic features of cancer stem cells: the emerging role of lipid 
metabolism. Oncogene 37, 2367-2378 (2018). 
153. K. Song et al., Active glycolytic metabolism in CD133(+) hepatocellular cancer stem 
cells: regulation by MIR-122. Oncotarget 6, 40822-40835 (2015). 
154. P. P. Liu et al., Metabolic regulation of cancer cell side population by glucose 
through activation of the Akt pathway. Cell Death Differ 21, 124-135 (2014). 
155. C. Dong et al., Loss of FBP1 by Snail-mediated repression provides metabolic 
advantages in basal-like breast cancer. Cancer Cell 23, 316-331 (2013). 
156. Y. Zhou et al., Metabolic alterations in highly tumorigenic glioblastoma cells: 
preference for hypoxia and high dependency on glycolysis. J Biol Chem 286, 32843-
32853 (2011). 
157. B. L. Emmink et al., The secretome of colon cancer stem cells contains drug-
metabolizing enzymes. J Proteomics 91, 84-96 (2013). 
158. J. Liao et al., Ovarian cancer spheroid cells with stem cell-like properties contribute 
to tumor generation, metastasis and chemotherapy resistance through hypoxia-
resistant metabolism. PLoS One 9, e84941 (2014). 
159. Y. A. Shen, C. Y. Wang, Y. T. Hsieh, Y. J. Chen, Y. H. Wei, Metabolic 
reprogramming orchestrates cancer stem cell properties in nasopharyngeal 
carcinoma. Cell Cycle 14, 86-98 (2015). 
160. P. Sancho et al., MYC/PGC-1alpha Balance Determines the Metabolic Phenotype 
and Plasticity of Pancreatic Cancer Stem Cells. Cell Metab 22, 590-605 (2015). 
161. M. Janiszewska et al., Imp2 controls oxidative phosphorylation and is crucial for 
preserving glioblastoma cancer stem cells. Genes Dev 26, 1926-1944 (2012). 
162. E. D. Lagadinou et al., BCL-2 inhibition targets oxidative phosphorylation and 
selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329-
341 (2013). 
163. T. Simsek et al., The distinct metabolic profile of hematopoietic stem cells reflects 
their location in a hypoxic niche. Cell Stem Cell 7, 380-390 (2010). 
164. W. Zhao et al., Candidate Antimetastasis Drugs Suppress the Metastatic Capacity of 
Breast Cancer Cells by Reducing Membrane Fluidity. Cancer Res 76, 2037-2049 
(2016). 
165. H. Ye et al., Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to 
an Adipose Tissue Niche. Cell Stem Cell 19, 23-37 (2016). 
166. C. L. Chen et al., NANOG Metabolically Reprograms Tumor-Initiating Stem-like 
Cells through Tumorigenic Changes in Oxidative Phosphorylation and Fatty Acid 
Metabolism. Cell Metab 23, 206-219 (2016). 
167. I. Samudio et al., Pharmacologic inhibition of fatty acid oxidation sensitizes human 
leukemia cells to apoptosis induction. J Clin Invest 120, 142-156 (2010). 
168. M. Humbert et al., Reducing FASN expression sensitizes acute myeloid leukemia 
cells to differentiation therapy. Cell Death Differ 10.1038/s41418-021-00768-1 
(2021). 
 95 
169. Y. Yasumoto et al., Inhibition of Fatty Acid Synthase Decreases Expression of 
Stemness Markers in Glioma Stem Cells. PLoS One 11, e0147717 (2016). 
170. A. Noto et al., Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating 
cells. Cell Death Dis 4, e947 (2013). 
171. A. Noto et al., Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via 
stabilization and nuclear localization of YAP/TAZ. Oncogene 36, 4573-4584 (2017). 
172. J. Li et al., Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of 
Ovarian Cancer Stem Cells. Cell Stem Cell 20, 303-314 e305 (2017). 
173. L. B. Hoang-Minh et al., Infiltrative and drug-resistant slow-cycling cells support 
metabolic heterogeneity in glioblastoma. EMBO J 37 (2018). 
174. R. Mitra, O. Chao, Y. Urasaki, O. B. Goodman, T. T. Le, Detection of lipid-rich 
prostate circulating tumour cells with coherent anti-Stokes Raman scattering 
microscopy. BMC Cancer 12, 540 (2012). 
175. L. Tirinato et al., Lipid droplets: a new player in colorectal cancer stem cells unveiled 
by spectroscopic imaging. Stem cells 33, 35-44 (2015). 
176. S. R. Singh et al., The lipolysis pathway sustains normal and transformed stem cells 
in adult Drosophila. Nature 538, 109-113 (2016). 
177. J. A. Ajani, S. Song, H. S. Hochster, I. B. Steinberg, Cancer stem cells: the promise 
and the potential. Semin Oncol 42 Suppl 1, S3-17 (2015). 
178. A. Recasens, L. Munoz, Targeting Cancer Cell Dormancy. Trends Pharmacol Sci 
40, 128-141 (2019). 
179. K. M. Havas et al., Metabolic shifts in residual breast cancer drive tumor recurrence. 
J Clin Invest 127, 2091-2105 (2017). 
180. P. J. Randle, Regulatory interactions between lipids and carbohydrates: the glucose 
fatty acid cycle after 35 years. Diabetes Metab Rev 14, 263-283 (1998). 
181. L. L. Listenberger, D. A. Brown, Fluorescent detection of lipid droplets and 
associated proteins. Curr Protoc Cell Biol Chapter 24, Unit 24 22 (2007). 
182. F. L. Shaw et al., A detailed mammosphere assay protocol for the quantification of 
breast stem cell activity. J Mammary Gland Biol Neoplasia 17, 111-117 (2012). 
183. B. Gyorffy, A. Lanczky, Z. Szallasi, Implementing an online tool for genome-wide 
validation of survival-associated biomarkers in ovarian-cancer using microarray data 
from 1287 patients. Endocr Relat Cancer 19, 197-208 (2012). 
184. E. Beck-Garcia, K. Beck-Garcia, A. Schlosser, W. W. Schamel, Analysis of 
interactions between proteins and fatty acids or cholesterol using a fatty 
acid/cholesterol pull-down assay. Anal Biochem 436, 75-77 (2013). 
185. E. Kaiser, R. L. Colescott, C. D. Bossinger, P. I. Cook, Color test for detection of 
free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 
34, 595-598 (1970). 
186. P. D. Adams et al., PHENIX: building new software for automated crystallographic 
structure determination. Acta Crystallogr D Biol Crystallogr 58, 1948-1954 (2002). 
187. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. 
Acta Crystallogr D Biol Crystallogr 66, 486-501 (2010). 
188. B. J. Hershey, R. Vazzana, D. L. Joppi, K. M. Havas, Lipid Droplets Define a Sub-
Population of Breast Cancer Stem Cells. J Clin Med 9 (2019). 
189. R. M. Neve et al., A collection of breast cancer cell lines for the study of functionally 
distinct cancer subtypes. Cancer Cell 10, 515-527 (2006). 
190. A. Prat et al., Phenotypic and molecular characterization of the claudin-low intrinsic 
subtype of breast cancer. Breast Cancer Res 12, R68 (2010). 
191. P. Greenspan, E. P. Mayer, S. D. Fowler, Nile red: a selective fluorescent stain for 
intracellular lipid droplets. J Cell Biol 100, 965-973 (1985). 
192. G. Dontu et al., In vitro propagation and transcriptional profiling of human mammary 
stem/progenitor cells. Genes Dev 17, 1253-1270 (2003). 
 96 
193. D. Ponti et al., Isolation and in vitro propagation of tumorigenic breast cancer cells 
with stem/progenitor cell properties. Cancer Res 65, 5506-5511 (2005). 
194. J. Kasurinen, A novel fluorescent fatty acid, 5-methyl-BDY-3-dodecanoic acid, is a 
potential probe in lipid transport studies by incorporating selectively to lipid classes 
of BHK cells. Biochem Biophys Res Commun 187, 1594-1601 (1992). 
195. D. S. Wishart et al., HMDB 4.0: the human metabolome database for 2018. Nucleic 
Acids Res 46, D608-D617 (2018). 
196. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, M. F. Clarke, 
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U 
S A 100, 3983-3988 (2003). 
197. R. W. Brownsey, A. N. Boone, J. E. Elliott, J. E. Kulpa, W. M. Lee, Regulation of 
acetyl-CoA carboxylase. Biochem Soc Trans 34, 223-227 (2006). 
198. J. P. Bonnefont et al., Carnitine palmitoyltransferases 1 and 2: biochemical, 
molecular and medical aspects. Mol Aspects Med 25, 495-520 (2004). 
199. D. L. Halvorson, S. A. McCune, Inhibition of fatty acid synthesis in isolated 
adipocytes by 5-(tetradecyloxy)-2-furoic acid. Lipids 19, 851-856 (1984). 
200. M. A. Lea, G. Weber, Inhibition of glycolytic enzymes of normal and neoplastic liver 
by free fatty acids. Biochem J 104, 37P (1967). 
201. Z. Zhang et al., PKM2, function and expression and regulation. Cell Biosci 9, 52 
(2019). 
202. F. Madeira et al., The EMBL-EBI search and sequence analysis tools APIs in 2019. 
Nucleic Acids Res 47, W636-W641 (2019). 
203. J. German, Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet 
93, 100-106 (1997). 
204. J. A. Macpherson et al., Functional cross-talk between allosteric effects of activating 
and inhibiting ligands underlies PKM2 regulation. Elife 8 (2019). 
205. V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, A stepwise huisgen 
cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and 
terminal alkynes. Angew Chem Int Ed Engl 41, 2596-2599 (2002). 
206. P. Wang, C. Sun, T. Zhu, Y. Xu, Structural insight into mechanisms for dynamic 
regulation of PKM2. Protein Cell 6, 275-287 (2015). 
207. S. Wu et al., Cellular, transcriptomic and isoform heterogeneity of breast cancer cell 
line revealed by full-length single-cell RNA sequencing. Comput Struct Biotechnol 
J 18, 676-685 (2020). 
208. F. Francescangeli et al., Proliferation state and polo-like kinase1 dependence of 
tumorigenic colon cancer cells. Stem Cells 30, 1819-1830 (2012). 
209. M. J. Thun, S. J. Henley, C. Patrono, Nonsteroidal anti-inflammatory drugs as 
anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer 
Inst 94, 252-266 (2002). 
210. C. Wang et al., Acetyl-CoA carboxylase-alpha inhibitor TOFA induces human 
cancer cell apoptosis. Biochem Biophys Res Commun 385, 302-306 (2009). 
211. M. G. Vander Heiden et al., Evidence for an alternative glycolytic pathway in rapidly 
proliferating cells. Science 329, 1492-1499 (2010). 
212. D. Y. Gui, C. A. Lewis, M. G. Vander Heiden, Allosteric regulation of PKM2 allows 
cellular adaptation to different physiological states. Sci Signal 6, pe7 (2013). 
213. S. L. Pinkosky et al., Long-chain fatty acyl-CoA esters regulate metabolism via 
allosteric control of AMPK beta1 isoforms. Nat Metab 2, 873-881 (2020). 
214. B. Viollet et al., AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol 
45, 276-295 (2010). 
215. B. van den Berg, P. N. Black, W. M. Clemons, Jr., T. A. Rapoport, Crystal structure 
of the long-chain fatty acid transporter FadL. Science 304, 1506-1509 (2004). 
 97 
216. Q. Li et al., Butyrate Suppresses the Proliferation of Colorectal Cancer Cells via 
Targeting Pyruvate Kinase M2 and Metabolic Reprogramming. Mol Cell Proteomics 
17, 1531-1545 (2018). 
217. C. Benesch et al., The clinicopathological and prognostic relevance of pyruvate 
kinase M2 and pAkt expression in breast cancer. Anticancer Res 30, 1689-1694 
(2010). 
218. Q. Zheng et al., Long noncoding RNA MEG3 suppresses liver cancer cells growth 
through inhibiting beta-catenin by activating PKM2 and inactivating PTEN. Cell 
Death Dis 9, 253 (2018). 
219. K. Taniguchi et al., MicroRNA-124 inhibits cancer cell growth through 
PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Lett 363, 17-27 
(2015). 
220. H. S. Shi et al., Silencing of pkm2 increases the efficacy of docetaxel in human lung 
cancer xenografts in mice. Cancer Sci 101, 1447-1453 (2010). 
221. D. Shang et al., Metformin increases sensitivity of osteosarcoma stem cells to 
cisplatin by inhibiting expression of PKM2. Int J Oncol 50, 1848-1856 (2017). 
222. I. Park et al., Changes in pyruvate metabolism detected by magnetic resonance 
imaging are linked to DNA damage and serve as a sensor of temozolomide response 
in glioblastoma cells. Cancer Res 74, 7115-7124 (2014). 
223. J. Chen et al., Shikonin and its analogs inhibit cancer cell glycolysis by targeting 
tumor pyruvate kinase-M2. Oncogene 30, 4297-4306 (2011). 
224. J. C. Boulos, M. Rahama, M. F. Hegazy, T. Efferth, Shikonin derivatives for cancer 
prevention and therapy. Cancer Lett 459, 248-267 (2019). 
225. L. E. Landree et al., C75, a fatty acid synthase inhibitor, modulates AMP-activated 
protein kinase to alter neuronal energy metabolism. J Biol Chem 279, 3817-3827 
(2004). 
226. M. Wu et al., Antidiabetic and antisteatotic effects of the selective fatty acid synthase 
(FAS) inhibitor platensimycin in mouse models of diabetes. Proc Natl Acad Sci U S 
A 108, 5378-5383 (2011). 
227. D. Jia, J. H. Park, K. H. Jung, H. Levine, B. A. Kaipparettu, Elucidating the 
Metabolic Plasticity of Cancer: Mitochondrial Reprogramming and Hybrid 















Appendix - List of collaborations 
 
This Ph.D. thesis includes results carried out with the support of valuable collaborations: 
 
• Flow cytometry and qPCR analyses were performed by the Scientific Service of 
Cogentech, IFOM, Milan (Italy); 
 
 
• The chemical synthesis of the lipid probe prop-2-yn-1-yl-2-(3-tridecyl-3-diazirin-
3-yl) acetate was conducted by Dmytro Yushchenko of the Institute of Organic 
Chemistry and Biochemistry of Prague (Czech Republic); 
 
 
• Structural and crystallization studies were conducted in by Dr. Sebastiano 
Pasqualato at the Biochemistry and Structural Biology Unit of the European 
Institute of Oncology (IEO) of Milan (Italy). 
 
 
 
 
 
